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KRAS mutation occurs in up to 60% of colorectal cancers (CRC) and development of 
effective targeted therapies still remains a formidable challenge. Studies have 
highlighted the issue of KRAS dependency and independency, implying that KRAS 
mutation status is inadequate as a biomarker of treatment response. There is a need to 
identify better biomarkers to predict response to proposed treatment strategies. 
Intratumoral heterogeneity in CRC tumors, however, hindered the establishment of a 
clinically derived KRAS dependency gene signature. Here, through integration of 
quantitative KRAS mutation pyrosequencing data and gene expression profiling in 
CRC tumors, we are able to define a KRAS dependency gene signature which 
exhibits enrichment in cell cycle and mitotic processes, together with elevated 
FOXM1 expression. We proposed a therapeutic strategy using CDK4/6 and MEK 
inhibitors that targets KRAS-driven molecular signature and reduces viability of 
KRAS-dependent and BRAF-mutant CRC via the synergistic depletion of FOXM1 
and reduction of other mitotic transcription factors E2F1 and CMYC, both in vitro 
and in vivo. Moreover, depletion of FOXM1 is able to subvert growth of KRAS-
dependent CRC. No toxicity was observed in vivo and, intriguingly, addition of 
CDK4/6 inhibitor reduces sensitivity of normal colon epithelial lines to MEK 
inhibitor, suggesting that this combination therapy could mitigate effects of MEK 
inhibition on normal noncancerous cells. Our study thus establishes KRAS 
dependency gene signature as a potential biomarker of response and the 
combinatorial inhibition of CDK4/6 and MEK as a promising treatment strategy 
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1.1 Colorectal Cancer 
Colorectal cancer arises from the large intestine which comprises of the ascending 
colon, transverse colon, descending colon, sigmoid colon and the rectum (NCI).The 
large intestine functions to absorb water and nutrients from food and to store and 
control excretion of fecal materials. Similar to most of the gastrointestinal tract, the 
large intestine consists of 4 layers (Figure 1.1) namely: the mucosa which is a 
columnar epithelium with numerous mucus-secreting goblet cells; the submucosa 
which contains blood vessels and submucous plexus; the muscularis propria where 
the circular and longitudinal muscles and myenteric nerve plexus are found; and 
lastly the serosa which consists of the visceral peritoneum. Tumor growth initiates 
from the mucosa layer and invades outwards to the sercosa. Adenocarcinomas 
originating from the epithelium of the mucosa make up more than 90% of all 
colorectal carcinoma (Bosman FT 2010), with neuroendocrine, spindle cell, 
adenosquamous, squamous and undifferentiated carcinomas making up the rest of the 
cases. 
Upon invasion of tumor cells beyond the mucosa layer as the tumor grows larger in 
size, there is an increase likelihood of colorectal cancer cells invading the blood or 
lymphatic vessels to metastasize to other sites in the body. Metastatic colorectal 
cancers are frequently presented in the liver due to the drainage of the venous blood 
flow from the large intestine into the hepatic portal vein leading into the liver. The 





Figure 1.1 Anatomy of the colon and rectum  







1.1.1 Epidemiology of Colorectal Cancer 
Colorectal cancer (CRC) is the third leading cause of death in all cancers in both male 
and female with an estimated 50,000 deaths and more than 130,000 new cases of 
CRC were expected to surface in the United States in 2015, making CRC the cancer 
with the third highest incidence rate (Siegel, Miller et al. 2015). Incidence of 
colorectal cancer increases with age, with the median age of diagnosis at about 70 
years in developed nations (Siegel, DeSantis et al. 2012). 
With improved treatment methods and screening, mortality has decreased in 
developed countries. Screening through colonoscopy allows for the removal of any 
premalignant adenomatous polyps at the same time, preventing the development of 
cancer. 5-year relative survival rate is 90% when CRC is detected at early stages 
(localized spread) but survival rate decreased drastically to 13% when the cancer has 
metastasized to distant organs (DeSantis, Lin et al. 2014). 
1.1.2 Treatment of Colorectal Cancer 
The treatment of colorectal cancer depends on the stage of the cancer at the time of 
diagnosis.  Colorectal cancer patients are stratified into the four stages based on the 
TNM staging criteria where T refers to the size of the tumor and the extent at which 
the tumor had spread through the walls of the colon; N indicates if the cancer cells 
has infiltrated into the nearby lymph nodes and the higher the number of lymph nodes 
involved, the higher the possibility of the systemic spread of the cancer; and M 
indicates the presence or absence of metastases at a distant organ or lymph nodes 
(Shia, Klimstra et al. 2012, 2014). Another factor to determine the appropriate 
treatment is the grade of the cancer (Derwinger, Kodeda et al. 2010). Low grade 
cancer means the cancer cells are highly differentiated and look similar to normal 
colorectal tissue and they are likely to grow slower and be less invasive. High grade 
cancer, however, displays poorly differentiated or undifferentiated morphology and 
indicates a poorer prognosis as these cancer cells tend to grow faster and are more 
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invasive. Thus, more aggressive treatment in terms of adjuvant chemotherapy may be 
given. 
Stage I and II CRC, where the tumor is confined within the colon, the cancer is 
curable through colostomy (Skibber 2001) by removing the section of the colon or 
rectum containing the tumor. When the cancerous cells have spread to the lymph 
nodes or beyond the walls of the colon (stage III), adjuvant chemotherapy and/or 
radiation may be given after surgical resection of the colon to improve survival by 
reducing recurrence (Sargent, Sobrero et al. 2009). Stage IV CRC, where the cancer 
had further metastasized to other organs or tissues, chemotherapy is mainly used in 
attempt to systemically remove metastases in the body and surgery and radiation may 
also be given to relieve blockage of colon caused by the primary tumor (Skibber 
2001, 2014).  
1.1.2.1 Treatment of metastatic colorectal cancer using conventional 
chemotherapy 
For metastatic CRC, till 2009, the first line treatment in CRC uses a combination of 
5-fluorouracil with leucovorin or capecitabine with either oxaliplatin (FOLFOX) or 
irinotecan (FOLFIRI) which is able to target and kill all rapidly growing and dividing 
cells, both normal and cancerous (Meyerhardt and Mayer 2005). 5-fluorouracil is the 
cornerstone of CRC treatment, inhibiting thymidylate synthase which is the rate-
limiting enzyme in pyrimidine nucleotides synthesis (Longley, Harkin et al. 2003). 
Combination with leucovorin enhances the ability of 5-fluorouracil to bind to 
thymidylate synthase. Oxaliplatin is a platinum-based drug which generates inter- and 
intra-strand cross linkages in DNA, preventing DNA replication and transcription 
(Graham, Mushin et al. 2004). Irinotecan is a topoisomerase I inhibitor and prevents 
type 1 topoisomerase from relieving supercoils formed during DNA replication and 
transcription (Wang 2002). There are many advances over the years in the 
development of chemotherapeutic drugs for advanced CRC, resulting in the increase 
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of the median overall survival time from 10 months with the use of fluorouracil in the 
1980s and 1990s to about 20 months using the current standard chemotherapy drugs 
in various combinations (Goldberg, Sargent et al. 2004).  However, even with better 
chemotherapeutic drugs, the median survival time stagnated at around 20 months. 
Furthermore, these cytotoxic drugs have very narrow therapeutic index, implying that 
the optimal effective dose is very close to the lethal dose. The flexibility to change 
the drug dosage to suit the patients’ response to the treatment is limited, especially for 
patients who do not respond. Thus, a new approach to CRC treatment is needed. 
1.1.2.2 Use of targeted therapy for metastatic colorectal cancer 
The past decades have seen unprecedented advances in the understanding of the 
molecular biology of cancer and this knowledge has aided identification of pathways 
and targets that are vital for the survival of the cancer cells. Development of specific 
small molecule inhibitors against kinases soon followed with hopes of abrogating the 
cancer cells and sparing the normal cells to improve treatment response and reduce 
adverse side effects which are almost certainly observed in the use of chemotherapy. 
Specifically in colorectal cancer, the use of monoclonal antibodies against vascular 
endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) 
together with chemotherapy are approved for use. 
The use of anti-VEGF therapy started due to the role of VEGF in mediating pro-
survival pathways in endothelial cells (Gerber, McMurtrey et al. 1998, Fujio and 
Walsh 1999) and endothelial cells are the building blocks of the formation of new 
vessels. By blocking the VEGF-activated pathways, tumor angiogenesis which is the 
sprouting of new vessels from existing vessels, together with the loss of adhesion 
between pericyte and endothelial cells, vasodilation, increased permeability of vessels 
and the integration of bone marrow-derived endothelial progenitor cells (Jain 2005), 
can be inhibited and tumor growth and metastasis can be hindered. Bevacizumab, the 
monoclonal antibody used in the treatment of metastatic CRC, binds to VEGF and 
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prevent it from interacting with its receptor on the endothelial cells. Phase III clinical 
trials using a chemotherapy regimen of irinotecan, fluorouracil and leucovorin with 
bevacizumab to treat metastatic CRC improved the median overall survival by 4.7 
months and progression free survival by 4.4 months as compared to the patients 
receiving only chemotherapy (Hurwitz, Fehrenbacher et al. 2004). This combination 
is currently used as one of the first-line treatments for metastatic CRC.  
Treatment with monoclonal antibody against EGFR prevents ligand binding of EGF 
to the extracellular domain of EGFR and this binding leads to the internalization of 
EGFR, preventing the activation of survival pathways in the cancers cells which 
present EGFR on their cell membranes. The binding of the antibody to EGFR could 
also trigger an immune response via the antibody dependent cellular cytotoxicity via 
the binding of its humanized immunoglobulin G1 heavy chain to the Fc receptors on 
phagocytic cells (Kurai, Chikumi et al. 2007). In the 2009 CRYSTAL phase III 
clinical trial, epidermal growth factor receptor EGFR monoclonal antibody, 
cetuximab was shown to be effective when used in combination with FOLFIRI as a 
First-Line therapy in metastatic CRC cases with KRAS (Kirsten Rat Sarcoma) wild 
type status and is therefore approved for use by FDA (Van Cutsem, Kohne et al. 
2009).  
However, based on phase III clinical trials, cetuximab is only effective in extending 
the overall survival time of patients with KRAS wild type status CRC. In KRAS 
mutant CRC, the use of cetuximab is ineffective due to the mutant KRAS being 
downstream of EGFR. With KRAS mutated, KRAS is constitutively activated and 
phosphorylates its downstream targets to activate the MEK/ERK and the PI3K/AKT 
pathway to promote cell cycle progression, transcription and cell survival. Its 
independence of upstream regulations and response to growth factors render 
inhibition of EGFR useless in the treatment of KRAS mutant CRC. Currently, KRAS 
mutation is used as a negative biomarker for the use of cetuximab and all patients 
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have to undergo KRAS mutation testing before cetuximab treatment can be 
administered (De Roock, Claes et al. 2010, Dienstmann, Vilar et al. 2011).  
This group of mutant KRAS CRC patients, that are ineligible for cetuximab targeted 
therapy, makes up about 40% of all CRC and more studies are emerging, showing 
that other common mutations such as PIK3CA and BRAF may cause cetuximab to be 
ineffective as well (Therkildsen, Bergmann et al. 2014). In chemotherapy-refractory 
CRC, it has also been shown that CRC with KRAS, BRAF, PIK3CA and PTEN loss 
are resistant to monoclonal anti-EGFR therapy (Luo and Xu 2014). Thus, it is 







Figure 1.2 Large percentage of colorectal cancer not responsive to EGFR 
monoclonal antibody treatment 
Only 15% of chemorefractory CRC are responsive to EGFR monoclonal 
antibody treatment and the rest are not responsive due to mutation in KRAS, 
BRAF, PIK3CA, loss of PTEN function and other molecular aberration that is 




1.1.3 Common molecular aberration in the progression of Colorectal Cancer 
1.1.3.1 Common mutations/alterations in CRC 
Some of the common alterations found in sporadic CRC include loss of adenomatous 
polyposis coli (APC) tumor suppressor, activating mutations in proto-oncogenes 
KRAS and BRAF and these are acquired early in the onset of tumorigenesis. Other 
commonly mutated genes included PIK3CA and p53. Loss of APC leads to 
constitutively activated WNT signaling as the role of APC is to promote beta-catenin 
degradation and prevent its nuclear localization where it can bind to T-cell factor-
lymphocytes factors to activate transcription of its target genes mainly involved in 
proliferation, survival and self-renewal in stem cells (Korinek, Barker et al. 1997, 
Anastas and Moon 2013). In recent study by The Cancer Genome Atlas Network, it 
was shown that about 93% of all CRC tumors showed altered WNT signaling with 
APC inactivated in 77% of all CRC tumors (2012). In the same study, alteration in 
receptor tyrosine kinase-RAS signaling, PI3K signaling and p53 signaling were 62%, 
50% and 61% respectively in CRC tumors (2012), showing that these 4 pathways 
including WNT signaling are most frequently altered pathways and perhaps the most 















Loss of genomic stability is the driver for CRC development and in about 80% of all 
sporadic CRC, chromosomal instability is the major cause of genomic instability 
(Lengauer, Kinzler et al. 1997). The chromosomal instability pathway (CIN) 
manifests through changes in chromosomal number and structures, leading to the loss 
of heterozygosity at multiple loci (Lengauer, Kinzler et al. 1997). These changes 
often led to physical loss of a functional copy of a tumor suppressor gene such APC, 
SMAD4 and p53, which roles are to prevent uncontrolled proliferation in cells by 
regulating the beta catenin pathway, mediating the TGF-beta signaling pathway in 
suppressing growth and arresting cell cycle and repairing any damage to the genomic 
material respectively (Campo, de la Calle-Martin et al. 1991, Goss and Groden 2000, 
Kinzler KW 2002, Miyaki and Kuroki 2003).  
Figure 1.3 Progression of colorectal cancer with common molecular 
alterations   
Diagram is extracted from (Walther, Johnstone et al. 2009). This simplified 
diagram shows the progression from an adenoma to carcinoma. Increasing 
chromosomal instability often takes place via the acquisition of KRAS mutation, 
followed by the loss of chromosome 18q containing SMAD4 and loss of p53 
functions. CRC driven by microsatellite instability often exhibit dysregulated 
WNT signaling (Grady and Carethers 2008), BRAF mutation (Rajagopalan, 
Bardelli et al. 2002) and aberration in the DNA mismatch repair genes, leading to 
positive selection for mutated TGF-beta receptor 2 (Parsons, Myeroff et al. 1995) 
and further mutation in BAX (Rampino, Yamamoto et al. 1997) and insulin-like 




In other sporadic CRC tumors, genomic instability arose differently through DNA 
mismatch-repair defects where there is methylation on the promoter of DNA 
mismatch-repair gene MLH1, resulting in microsatellite instability (MSI) (Deng, 
Peng et al. 2002). Microsatellites are nucleotide repeat sequences scattered along the 
genome and DNA polymerases are error-prone when copying short repeat sequences 
and require mismatch-repair genes to repair the mistakes. Loss of function of MLH1 
on both alleles leads to inability to repair strand slippage and this changes the length 
of microsatellite, leading to the microsatellite instability phenotype (Boland and Goel 
2010). 
Another mechanism of genome instability results from the aberrant methylation of 
CpG islands in the genome (Weisenberger, Siegmund et al. 2006) and this 
phenomenon is termed as CpG island methylator phenotype (CIMP). CpG islands are 
cytosine and guanine rich regions often found at the gene promoters and are mostly 
unmethylated in a normal cell (Carninci, Sandelin et al. 2006). When the CpG islands 
at the promoter region are hypermethylated, transcription of the respective genes are 
repressed. Often in CRC, the genes that are silenced via CpG methylation are mostly 
involved in mismatch-repair such as MLH1, MINT1, MINT2 and MINT3 (Toyota, 
Ahuja et al. 1999, Issa 2004, Barault, Charon-Barra et al. 2008), thus these CRC 
tumors also display microsatellite instability. 
1.1.3.2 Adenoma to carcinoma progression in Colorectal Cancer 
Tumorigenesis in colorectal cancer usually follows the adenoma-carcinoma 
development where it begins with a benign adenomatous polyp from colon lumen 
epithelium (Kinzler KW 2002) (Figure 1.3). Upon acquisition of more mutations, the 
cells in the polyp proliferate rapidly to form larger adenoma. Defects in the DNA 
repair machinery permit the accumulation of mutations as the cells continue to divide. 
Activating mutations in KRAS, a small GTPase (guanosine triphosphatase) and 
PIK3CA, a catalytic subunit of phosphoinositide-3-kinase (PI3K) are common as they 
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drive the growth and survival signaling pathways in the cells (Baba, Nosho et al. 
2011). Chromosomal instability often increases upon the acquisition of KRAS 
mutation and followed by the loss of chromosome 18q containing SMAD4 and loss 
of p53 function due to mutation and loss of chromosome 17. CRC driven by 
microsatellite instability often exhibit dysregulated WNT signaling (Grady and 
Carethers 2008), BRAF mutation (Rajagopalan, Bardelli et al. 2002) and the 
aberration in the DNA mismatch repair genes, leading to positive selection for 
mutated TGF-beta receptor 2 (Parsons, Myeroff et al. 1995) and further mutation in 
pro-apoptotic BAX (Rampino, Yamamoto et al. 1997) and insulin-like growth factor 
2 receptor (Souza, Appel et al. 1996) leading to p53-independent progression to 
carcinoma. 
If left untreated, the adenoma will develop into an early carcinoma as the cancerous 
cells spread to the surrounding tissue (Baker, Fearon et al. 1989, Baker, Markowitz et 
al. 1990). As the tumor grows, it develops a network of blood supply, a process 
termed angiogenesis to obtain sufficient nutrients and oxygen to maintain its 
excessive growth rate (Wyckoff, Jones et al. 2000). The cancerous cells then can 
enter the blood circulation via these or other blood vessels or they could indirectly 
enter the blood stream via the lymphatic system (Chambers, Groom et al. 2002). This 
is why the presence of cancerous cells in the draining lymph nodes is an indicator of 
the progression of the cancer beyond its primary site.  
To successfully metastasize, the cancer cells in the blood stream have to arrest at a 
distant organ and extravasate into the tissue surrounding the vessel. The common 
sites of CRC metastasis are liver, peritoneum and lungs. Once they are lodged in their 
new site, they have to establish their own network of blood supply in order to grow 
(Chambers, Groom et al. 2002). 
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1.2 RAS superfamily of GTPases 
The RAS superfamily comprises 154 members which are small GTPases including 
the founding members HRAS, NRAS and KRAS. They are segregated into 5 main 
families according to their sequence and functions namely: Ras, Rho Rab, Arf and 
Ran (Colicelli 2004). 
Ras family members are mainly involved in the regulation of extracellular signal 
transduction to the intracellular signaling networks that controls cell proliferation and 
survival. Rho family members are also involved in signal transduction but they signal 
to pathways that regulate actin cytoskeleton organization and this affects cell 
movement, polarity and shape. Rab and Arf family members regulate membrane 
trafficking and intracellular transport and Ran regulates the transport of 
macromolecules between the nucleus and cytoplasm and the spindle organization 
during mitosis. 
1.2.1 KRAS 
Kirsten rat sarcoma viral oncogene homolog, KRAS, belongs to the RAS superfamily 
of small GTPases proteins which bind and hydrolyze guanosine triphosphates (GTP) 
to guanosine diphosphates (GDP), leading to their activation and subsequently the 
phosphorylation and activation of their downstream targets. It has 2 protein isoforms, 
KRAS4A and KRAS4B due to alternative splicing at the KRAS locus (Malumbres 
and Barbacid 2003). Together with the other RAS family members HRAS and 
NRAS, they share over 90% similarity in sequences in the first 168 amino acids but 
differ in the hypervariable regions at the C-terminal which affect their subcellular 
membrane localization as well as plasma membrane targeting (Bourne, Sanders et al. 
1991, Hancock 2003). The mammalian homologues of KRAS together with Harvey-
RAS was first discovered in the rat genome through the studies of Kirsten murine 




KRAS, is a proto-oncogene that is frequently mutated in many cancers; it is estimated 
to occur at about 90% in pancreatic adenocarcinoma (Almoguera, Shibata et al. 1988, 
Capella, Cronauer-Mitra et al. 1991), 40% in colorectal cancer (Vaughn, Zobell et al. 
2011) and 30% in lung cancer (Capella, Cronauer-Mitra et al. 1991).  
1.2.2 Regulation of KRAS activation 
In normal, non-transformed cells, activation of KRAS require the presence of growth 
factors that bind and activation the receptor tyrosine kinases (RTK) found on the 
cellular membrane. Epidermal growth factor receptors upon binding to their ligands, 
mitogenic signals, lead to phosphorylation of tyrosine residues in their intracellular 
domains (Figure 1.4). Activated RTKs then recruit adaptor proteins such as Growth 
factor receptor- bound protein 2 (GRB2) through recognition and binding to the Src-
homology domain (SH2 in the adaptor proteins) (Buday and Downward 1993, 
Okutani, Okabayashi et al. 1994). GRB2 also binds indirectly to RTK via another 
adaptor protein, src homology and collagen domain protein (SHC) (Schlessinger and 
Bar-Sagi 1994). Son of the sevenless (SOS) bound to Grb2 through the SH3 domain 
is then brought to close to the plasma membrane where inactive KRAS is found 
(Chardin, Camonis et al. 1993). SOS, a guanine nucleotide exchange factor, acts to 
catalyze the exchange of GDP to GTP, promoting the formation of active RAS-GTP 
complexes (Bar-Sagi 1994).KRAS has a weak intrinsic GTPase activity and the 
binding of a GTPase-activating protein, GAP, such as p120 RASGAP or 
neurofibromin increases the rate of catalysis of GTP to GDP, inactivating KRAS and 
stopping the downstream signaling cascade (Scheffzek, Ahmadian et al. 1998, 
Cichowski and Jacks 2001, Donovan, Shannon et al. 2002).  
Activation of RAS also requires that a series of post-translational modifications at the 
C-terminal which is important to direct it to the various cellular membranes and for 
RAS to be activated by its upstream RTK, it needs to be first localized at the plasma 








Figure 1.4 RAS activation via ligand binding to receptor tyrosine kinase 
Diagram is adapted from (Kholodenko 2003). Upon ligand/mitogens binding to 
the extracellular domain of receptor tyrosine kinase (RTK) such as epidermal 
growth factor receptor, tyrosine residues in their intracellular domains are 
phosphorylated (YP), leading to recruitment of adaptor proteins growth factor 
receptor-bound protein 2 (GRB2) directly or indirectly through src homology and 
collagen domain protein (SHC). Son of sevenless (SOS), a guanine nucleotide 
exchange factor, bound to GRB2 is then brought into close proximity to inactive 
RAS at the plasma membrane. SOS then catalyzes the exchange of GDP to GTP, 




1.2.3 Regulation of RAS signaling 
1.2.3.1 Regulation of downstream MAPK signaling 
RAF family consists of 3 serine/threonine kinase members A-RAF, B-RAF and C-
RAF, with B-RAF being the member most frequently mutated in cancer. Upon 
formation of active RAS-GTP complex, RAF is recruited and bound to the effector 
loop of the RAS isoform via its RAS-binding domain (RBD) in the N-terminus 
(Vojtek, Hollenberg et al. 1993) and this disrupts the inhibitory interaction between 
the adjacent cysteine rich domain and the catalytic domain in RAF (Cutler, Stephens 
et al. 1998). The binding of RAS also interrupts the interaction between 14-3-3 that 
stabilizes the inactive state of RAF (Light, Paterson et al. 2002), leading to the 
dephosphorylation of serine 259 by protein phosphatase 2A (Ory, Zhou et al. 2003) 
(Figure 1.5). This results in a conformational change in RAF that primes it for 
subsequent activating phosphorylation at serine 338 (S338) and threonine 341 (Y341) 
with the latter likely due to Src-family kinases or casein kinase 2 (Marais, Light et al. 
1997). These 2 sites of phosphorylation enable interaction with MEK1 and MEK2 
and lead to phosphorylation on serine 218/222 and serine 222/226 respectively 
(Zheng and Guan 1994, Shaul and Seger 2007), and subsequently, activated MEK1/2 
then phosphorylates and activates downstream ERK1 on tyrosine 202 and threonine 
Y204 (Ferrell and Bhatt 1997) and ERK2 on tyrosine 185 and threonine 187 
(Haystead, Dent et al. 1992, Burack and Sturgill 1997).  
This signaling cascade is aided by the recruitment of Kinase repressor of KRAS 
(KSR) to the RAS-GTP complex, where it functions as a scaffold to bring MEK and 
ERK proteins into close proximity to the RAF proteins, facilitating the activation of 
the MAPK pathway (Roy, Laberge et al. 2002). Dimerization between different 
members of the RAF kinases can result in allosteric activation by the B-RAF kinase 
on its other family members, driving downstream phosphorylation and activation 
(Hu, Stites et al. 2013). The interaction and dimerization between the RAF family and 
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other kinases is complex, not surprisingly as this is the start of the signaling cascade 









Figure 1.5 Core RAS-activated MAPK signaling 
Diagram is adapted from (Lavoie and Therrien 2015). Simplified diagram shows 
the activation of MAPK signaling after RAS activation. RAF binds to activated 
RAS and this disrupts inhibitory interaction between 14-3-3 and RAF. 
Dephosphorylation of S259 on RAF leads to conformation change in RAF. Src-
family kinases and casein kinase 2 (CAK2) subsequently phosphorylated RAF on 
S338 and Y341. RAF then phosphorylates MEK1 and MEK2 on S218/222 and 
S222/226 respectively. Activated MEK1/2 further phosphorylates ERK1 and 
ERK2 on Y202/204 and Y185/187 respectively. KSR1/2 functions as a scaffold to 
bring the components of the MAPK signaling into close proximity of each other to 
facilitate signaling. More details in text. 
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Phosphorylated ERK1/2 further catalyze the phosphorylation of its cytoplasmic 
substrates such as 90kDa ribosomal S6 kinases (p90RSK) family, consisting RSK1-4 
(Roux and Blenis 2004) as well as multiple nuclear transcription factors driving 
processes such as proliferation, survival, differentiation, angiogenesis, migration and 
chromatin remodeling (Dunn, Espino et al. 2005, Yoon and Seger 2006). The 
temporal differences in the strength of activation and cellular localization of ERK 
determines the activation of the processes (Murphy and Blenis 2006). Early gene 
products such as MYC, JUN, FOS and EGR-1 induced by ERK signaling may 
function as sensors detecting ERK signaling dynamics through their expression level 
and phosphorylation and duration of phosphorylation (Murphy, Smith et al. 2002, 
Murphy, MacKeigan et al. 2004). Only sustained ERK signaling promotes the 
phosphorylation and stabilization of genes such as cyclin D1, thus promoting entry to 
cell cycle. 
Activated ERK also regulates the MAPK signaling via a negative feedback loop 
where it inhibits RAF via phosphorylation, leading to RAS binding inhibition and 
disruption of BRAF-CRAF complexes (Dougherty, Muller et al. 2005, Ritt, Monson 
et al. 2010). Activated ERK also phosphorylates SOS1, inhibiting its and RAS 
activity (Corbalan-Garcia, Yang et al. 1996). It also induces the expression of dual-
specificity phosphatases (DUSPs) and Sprouty, which dephosphorylate ERK and 
impair RAS activation by tethering GRB2 away from SOS respectively (Hanafusa, 






1.2.3.2 Other downstream effectors of RAS signaling 
RAS-GTP can also bind directly to phosphatidylinositol-3-kinase (PI3K) and 
allosterically activate it via the activation of its p110 catalytic subunit (Ong, Hadari et 
al. 2001) (Figure 1.6). PI3K then catalyzed the generation of phosphatidylinositol-3, 
4, 5-triphosphate (PIP3), which recruits the protein kinase AKT to the membrane 
where it is activated by phosphorylation at threonine 308 and serine 473 by 3-
phosphoinositide-dependent kinase 1 (PDK1) and mTORC2 complex (Alessi, James 
et al. 1997, Sarbassov, Guertin et al. 2005) respectively. Activated AKT signals 
downstream to drive protein synthesis through mTORC1 (Wang and Proud 2006), 
survival through its inhibition on pro-apoptotic proteins, cell cycle through cyclin D1 
(Liang and Slingerland 2003), p21 and p27 (Testa and Bellacosa 2001), metabolism 
and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) 
pathway (Romashkova and Makarov 1999). AKT pathway thus has been found to be 
dysregulated in cancer and its downstream targets shown to be important in 








Figure 1.6 Activation of PI3K/AKT pathway and its downstream effectors. 
Diagram is adapted from (http://www.sfb773.de/html/projectC5.html). 
Activation of receptor tyrosine kinase activate PI3K (p85 and p110 subunits) and 
PI3K then catalyzed the generation of phosphatidylinositol 3, 4, 5 triphosphate 
(PIP3) from phosphatidylinositol-3,4-diphosphate (PIP2), which recruits the 
protein kinase AKT to the membrane where it is activated by phosphorylation by 
3-phosphoinositide-dependent kinase 1 (PDK1) and mTORC2 complex. 
Activated AKT signals downstream to drive protein synthesis through mTORC1 
(Wang and Proud 2006), survival through its inhibition on pro-apoptotic proteins  
(Bad and Casp9), cell cycle through cyclin D1, p21, p27 and MDM2 and the 
nuclear factor kappa-light-chain-enhancer of activated B cells to prevent cell 
death. Activated RAS can activate p110, the catalytic subunit of PI3K. PTEN 




1.2.4 Role of KRAS in cancer 
KRAS mutation is found in multiple cancer types and its role in driving 
tumorigenesis has been well established (Lawrence, Stojanov et al. 2014). In CRC, 
the most frequent KRAS mutation in is on codon 12 and 13, followed by codon 61. 
Mutations on G12 and G13 account for more than 99% of all mutations, with G12D, 
G12V and G13D contributing 35%, 20% and 19% respectively (Prior, Lewis et al. 
2012). Substitution in codon 12 and 13 results in steric hindrance which prevents van 
der Waals bonds formation between RAS and GAP and this disturbs the orientation 
of catalytic glutamine in codon 61, attenuating GTP hydrolysis (Scheffzek, Ahmadian 
et al. 1997). Similarly, a direct substitution in glutamine 61 other than glutamic acid 
will also block GTP hydrolysis (Der, Finkel et al. 1986). With impaired GTP 
hydrolysis, KRAS is trapped in a GTP-bound activated state, constitutively driving its 
downstream effector pathway signaling. 
1.2.5 Challenges in KRAS mutant cancer treatment 
In the past, mutant KRAS was considered to be not targetable via pharmacological 
inhibition presumably due to its nucleotide-binding pocket of KRAS protein having 
very high affinity for GTP (Young, Lyons et al. 2009, Baines, Xu et al. 2011). 
Alternative strategy to block RAS activation indirectly was to inhibit 
farnesyltransferase, which is required for the farnesylation of RAS. This post-
translational lipid modification of RAS allows the binding of RAS to the membrane 
and its subsequent activation but in the presence of farnesyltransferase inhibitors, 
KRAS and NRAS are still activated due to the geranylgeranyltransferase providing 
sufficient lipid modification (James, Goldstein et al. 1996, Whyte, Kirschmeier et al. 
1997). Thus, there is switch of focus to target KRAS mutant cancer by inhibiting its 
downstream signaling, specifically the MAPK pathway. 
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1.2.6 RAF inhibition predominantly ineffective in KRAS mutant cancer 
The BRAF inhibitors used in the clinical such as vemurafenib and dabrafenib, 
suppress RAF activity effectively in cancer cells harboring BRAF(V600E) mutation. 
In BRAF wild type cancer cells, in the presence of oncogenic RAS, non-saturating 
BRAF inhibition can lead to activation of CRAF through RAS-dependent BRAF 
binding to CRAF, ultimately activating MEK-ERK signaling (Heidorn, Milagre et al. 
2010). This transactivation of RAF via dimerization reveals the importance of 
inhibition of CRAF as well as BRAF even though BRAF has a higher basal activity 
than CRAF (Mason, Springer et al. 1999) and is mutated at a higher frequency. The 
use of sorafenib, a multi-kinase inhibitor, which is developed as a wild type CRAF 
and BRAF inhibitor, has showed promising efficacy in combination with 
chemotherapy in phase I/II clinical trials in KRAS mutant cancers (Dingemans, 
Mellema et al. 2013, Samalin, Bouche et al. 2014), suggesting that this may be a 
treatment strategy for KRAS mutant cancers. However, toxicity to normal cells may 
limit the dosage used since sorafenib or similar inhibitors target wild type CRAF and 
BRAF which are also important in normal cells. 
1.2.7 Use of MEK inhibitors in clinical trials for CRC 
Since MEK1 and MEK2 are positioned directly downstream of RAS and RAF, 
multiple highly selective MEK inhibitors have been designed and tested in the 
clinical trials. Currently the only clinically approved MEK inhibitor is trametinib for 
the treatment of metastatic melanoma with BRAF(V600E/K) mutation which 
improved overall survival and progression-free survival (Flaherty, Robert et al. 2012). 
However, such efficacy is not observed with single MEK inhibitor treatment in 
KRAS mutant cancer. This is likely due to the toxicity in normal cells limiting the 
dose used and lack of enrichment of KRAS mutant patient cohorts (Rinehart, Adjei et 
al. 2004, Haura, Ricart et al. 2010). Moreover, RAS signaling to multiple downstream 
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effectors other than the MAPK pathway could be the reason as to why single MEK 
inhibition is ineffective due to activated compensatory pathways still present. 
Most of the MEK inhibitors are reversible, allosteric inhibitors that bind to a site 
adjacent to the ATP-binding site on MEK1 and MEK2 (Samatar and Poulikakos 
2014). PD0325901, a second generation MEK1/2 inhibitor, inhibits MAPK signaling 
by binding to MEK1/2 and inhibit their kinase activity, thus preventing the 
phosphorylation of downstream ERK1/2. Trametinib, the only approved MEK 
inhibitor for clinical use, inhibits both MEK1/2 kinase activity as well as RAF-
dependent phosphorylation of MEK1 on serine 217, preventing dual phosphorylation 
and complete activation of MEK1 and MEK2 (Gilmartin, Bleam et al. 2011).  
1.2.7.1 Compensatory pathways leading to MEK inhibitor inefficacy 
1.2.7.1.1 PI3K/AKT pathway activation/dependence upon MEK inhibition 
Ebi et al showed that upon MEK inhibition in KRAS mutant cancer, there is an 
increase in AKT phosphorylation via the increased association of the PI3K and IRS 
proteins (insulin receptor substrate is an adaptor protein which recruits PI3K to RTK 
via association with p85 subunit) as well as the increased phosphorylation in insulin 
like growth factor 1 receptor (IGF-1R) (Ebi, Corcoran et al. 2011). MEK inhibition 
resulted in decrease in TORC1 activation downstream, leading to the loss of feedback 
inhibition of TORC1 on IRS. Recently, phosphorylated ERK has been shown to 
transcriptionally activate the negative regulators of mTORC1 such as TSC1, TSC2, 
Deptor and REDD1 (Komatsu, Fujita et al. 2015).  
She et al showed that in tumors with both PIK3CA and KRAS mutation, single 
inhibition is insufficient in blocking cap-dependent translation (She, Halilovic et al. 
2010). Only when both MEK and AKT pathways are inhibited, there is 
dephosphorylation of 4EBP1and the binding of unphosphorylated 4EBP1 to eIF4E 
inhibit cap-dependent translation, decreasing cell viability. 
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Mutation in PIK3CA in KRAS mutant cancers reestablishes cyclin D1 expression and 
G1-S phase progression in cell cycle via constitutive activation of AKT signaling, 
rendering cyclin D1 expression and therefore cell cycle progression, independent of 
KRAS/MEK/ERK signaling (Halilovic, She et al. 2010). 
Sun et al showed once again AKT pathway involvement in MEK inhibition resistance 
in KRAS mutant CRC and lung cancer via a MYC-dependent transcription 
upregulation of ERBB3, the kinase-defective member of the ERBB receptor tyrosine 
kinase family (Sun, Hobor et al. 2014). Increase in phosphorylated AKT and 
phosphorylated ERBB3 were induced upon MEK inhibition, promoting cell survival. 
Only MEK inhibitor treatment together with afatinib, a dual EGFR/ERBB2 inhibitor 
which can block the formation of kinase-active heterodimer between ERBB3 and its 
binding partners EGFR and ERBB2, and prevent the downstream activation of AKT 
pathway and induce apoptosis. 
1.2.7.1.2 Re-activation of RAF 
Upon the MEK inhibition, phosphorylation of ERK decreases together with its 
inhibitory phosphorylation on CRAF (Dougherty, Muller et al. 2005) and after time, 
this leads to the induction of RAF-MEK complexes and CRAF-dependent 
reactivation of ERK (Lito, Saborowski et al. 2014), preventing the durable inhibition 
of ERK. Through this finding, there is increased interest in newly improved MEK 
inhibitor that inhibits MEK activity as well as prevent CRAF reactivation as this may 
improve MEK inhibitor efficacy in KRAS mutant cancer. 
1.2.7.1.3 MEK inhibition alone insufficient in eliciting death signals 
Suppression of ERK phosphorylation via MEK inhibition induces expression of pro-
apoptotic BIM but with no reduction in the expression of anti-apoptotic protein BCL-
xL, BCL-2 and MCL-1. This negates the increase in BIM levels as the anti-apoptotic 
proteins formed inhibitory complexes with BIM, preventing apoptosis. Only upon 
treatment with BCL-xL and MEK inhibitors, formation of BCL-XL and BIM 
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complexes is inhibited and the increased level of BIM then induces apoptosis in 
KRAS mutant cancer (Corcoran, Cheng et al. 2013). 
The identification of compensatory pathway activation or dependence in KRAS 
mutant cancer upon MEK inhibition leads to the idea of combinatorial treatment 
strategies and various treatment strategies were proposed and are currently being 
tested out in clinical trials. 
1.2.8 Development of ERK inhibitors 
Upon the discovery of negative feedback loops in the RAF/MEK/ERK pathway as 
well as RAF and MEK inhibitors resistance that result in the reactivation/recovery of 
ERK (Lito, Saborowski et al. 2014), development of specific ERK inhibitors started. 
Currently, SCH900353, a specific inhibitor able to inhibit both ERK1 and ERK2 
intrinsic kinase activity and prevent their phosphorylation by MEK, is in phase I 
clinical trials (Chaikuad, Tacconi et al. 2014, Deng, Shipps et al. 2014). Other ERK 
inhibitors are either in very early phases of clinical testing or still in preclinical 
studies and are unlikely to be available for clinical use in the near future. 
1.2.9 KRAS direct inhibitors 
In 2013, Ostrem et al developed small molecule inhibitors that bind specifically to 
KRAS with G12C mutations, disrupting switch I and II and causing the mutant 
KRAS G12C to favor binding to GDP instead of GTP (Ostrem, Peters et al. 2013). 
This inactivates mutant KRAS and also prevent it from binding to RAF without 
affecting the activity of wild type RAS. 
Attempts to interfere with the subcellular localization and activation of RAS have 
been successful in preclinical studies using deltarasin which binds to the farnesyl-
binding pocket of prenyl-binding protein PDEδ. Deltarasin inhibits the interaction 
between KRAS and PDEδ interaction, and relocalized mutant KRAS proteins to the 
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endomembranes, thus suppressing mutant KRAS signaling and inhibiting tumor 
growth (Zimmermann, Papke et al. 2013). 
Stabilized alpha helices of son of sevenless 1 (SAH-SOS1) peptides also were 
recently developed and shown to be able to disrupt KRAS and SOS1 interaction and 
prevent nucleotides from binding to wild type and mutant KRAS (Leshchiner, 
Parkhitko et al. 2015) and therefore inhibiting downstream KRAS signaling in vitro. 
These KRAS direct inhibitors mentioned above are still in preliminary preclinical 
testing stages and much more characterization and validation in vivo models need to 
be done. Another potential challenge in targeting KRAS directly is the phenomenon 
of KRAS independence which a few studies have shown that in KRAS mutant cancer 
lines, some are resistant to the knockdown of KRAS (Scholl, Frohling et al. 2009, 
Singh, Greninger et al. 2009, Singh, Sweeney et al. 2012). This strategy may not be 





1.3 CDK4/6 pathway 
Cyclin-dependent kinase 4 and 6 (CDK4/6) belong to the family of cyclin-dependent 
kinases which have important functions in cell cycle and transcription and their 
activity are dependent on their binding to specific cyclin subunits.  There are 11 
classical CDK ranging from CDK1 to CDK11. CDK4/6 specific binding cyclin 
subunits are cyclin D1, D2 and D3 and they share over 50% similarity in their amino 
acid sequences (Xiong, Menninger et al. 1992). 
1.3.1 Functions of CDK4/6 
1.3.1.1 CDK4/6 regulates G1 to S phase transition in cell cycle 
In the classical model of cell cycle in mammalian cells, the specific formation of 
cyclins-CDKs complexes drive the cell cycle progression in an orderly and sequential 
manner. In G1 phase, the accumulation of cyclin D leads to the formation of active 
CDK4/6-cyclin D complexes, which partially inactivate retinoblastoma (RB), a tumor 
suppressor, to promote the expression of cyclin E. Cyclin E then binds to CDK2, 
forming cyclin E-CDK2 complexes that further inactivate RB and to drive expression 
of genes required for S phase (Lundberg and Weinberg 1998, Harbour, Luo et al. 
1999). During the late stage of DNA replication in S phase, CDK2 is then activated 
by cyclin A2 to drive transition from S phase to G2 phase(Yam, Fung et al. 2002). 
Cyclin A2 is thought to then binds to  and activate CDK1 to mediate the onset of 
mitosis (Malumbres and Barbacid 2009). Upon the disintegration of the nuclear 
envelope, cyclin A is degraded, enabling the formation of cyclin B-CDK1 complexes 
to drive mitosis (den Elzen and Pines 2001, Jackman, Lindon et al. 2003, Malumbres 
and Barbacid 2005).  
In normal cells, activated cyclin D-CDK4/6 and cyclin E-CDK2 complexes, through 
their combined phosphorylation of RB, drive cells pass the restriction point, 
committing the cell to cell cycle. When CDK4 and CDK6 were genetically ablated in 
mice models, development of most organs and tissues were unaffected and isolated 
 28 
 
mouse embryonic fibroblasts from these mice were still able to undergo proliferation 
(Malumbres, Sotillo et al. 2004). CDK2 knockout mice are shown to be viable and it 
is essential only in meiosis but not mitosis (Berthet, Aleem et al. 2003, Ortega, Prieto 
et al. 2003), suggesting that there is redundancy in the functions of CDK2 and 
CDK4/6 in cell cycle in normal mammalian cells. In colon cancer cells, however, 
inhibition of CDK4 was sufficient to cause G1 arrest but inhibition of CDK2 did not 
prevent cell cycle progression, suggesting that CDK4/6 has a greater role in driving 
cell cycle entry in cancer as compared to CDK2 (Tetsu and McCormick 2003). 
Loss of CDK4/6 activity can lead to senescence through the loss of phosphorylation 
on RB and FOXM1, leading to the inhibition of G1-S transcriptional program driven 
largely by E2F and FOXM1 transcription factors (Anders, Ke et al. 2011). 
1.3.1.2 Role of CDK4/6 in development 
Studies in mice have shown CDK4 to be important during postnatal development for 
the proliferation of pancreatic β-cells and pituitary lactrotrophs (Rane, Dubus et al. 
1999, Tsutsui, Hesabi et al. 1999)and loss of CDK6 to only results in minor defects 



















Figure 1.7 Regulation of CDK4/6-cyclin D complex and its role in cell cycle 
Diagram is adapted from (VanArsdale, Boshoff et al. 2015). In early G1 phase, 
RB is hypophosphorylated, sequestering E2Fs and forming repressive 
transcriptional complexes with histone deacetylases, preventing the 
transcription of S-phase and G2/M phase genes driven by E2Fs. CDK4/6 
monomer activity is inhibited by p27. Upon mitogen stimulation and activation 
of upstream MAPK and PI3K/AKT pathway, cyclin D accumulates via 
increased transcription and translation and decreased degradation, forming 
active CDK4/6-cyclin D complexes facilitated by phosphorylated p27. These 
complexes together with CDK2-cyclin E complexes then phosphorylate and 
inactivate RB, releasing E2Fs, allowing for transcription of genes regulated by 
E2Fs and transition from G1 phase to S phase. This FOXM1 is also 
phosphorylated and activated by active CDK4/6-cyclin D complexes, leading to 
transcription of FOXM1 target genes, driving pro-oncogenic signaling and 
preventing cellular senescence  
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1.3.2.1 Cyclin D availability 
Activation of CDK4/6 requires the binding of its catalytic partners, cyclin D1, D2 or 
D3. Cyclin D expressions change throughout the different phases of cell cycle 
according to the presence of external mitogenic stimuli (Sherr and Roberts 1999). 
Increase in cyclin D protein level could be due to increase in transcription of cyclin D 
genes by transcription factors activated by mitogenic signals such as CMYC, FOS 
and JUN (Brown, Nigh et al. 1998, Bouchard, Thieke et al. 1999, Klein and Assoian 
2008), increased cyclin D protein translation via PI3K/AKT/mTOR/S6 kinase 1 
signaling (Muise-Helmericks, Grimes et al. 1998), or GSK3β inhibition preventing 
the phosphorylation of cyclin D at its C-terminus, leading to its stabilization and 
nuclear localization (Diehl, Cheng et al. 1998, Alt, Cleveland et al. 2000). 
1.3.2.2 Regulation by Cip/Kip proteins 
Another layer of regulation is contributed by the Cip/Kip proteins namely, p21, p27 
and p57. In the presence of antiproliferative signals, unphosphorylated p21 and p27 
directly inhibit CDK4/6 by blocking its kinase site (Harper, Elledge et al. 1995, Ray, 
James et al. 2009). However, upon phosphorylation of p21 and p27 at tyrosine 76 and 
tyrosine 88 and 89 respectively, Cip/Kip proteins release their inhibitory blockage of 
CDK4/6 kinase site, allowing for phosphorylation of CDK4/6 to take place (James, 
Ray et al. 2008, Hukkelhoven, Liu et al. 2012). Moreover, Cip/Kip proteins have 
been observed to be bound to active cyclin D-CDK4/6 complexes (Kaldis, Ojala et al. 
2001) and since they harbor bipartite nuclear localization sequences absent in 
CDK4/6, they could possibly mediate the nuclear localization of CDK4/6, granting 
them access to their substrates (LaBaer, Garrett et al. 1997, Cheng, Olivier et al. 
1999). 
Likely after the formation of the ternary complex of cyclin D-CDK4/6 and Cip/Kip 
proteins, phosphorylation of the activation loop or T-loop at threonine 172 in CDK4 
and threonine 177 in CDK6 take place to enable the full activation of the kinases, 
with the T-loop then facilitating the binding of cyclin and substrates (Kato, Matsuoka 
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et al. 1994, Bockstaele, Kooken et al. 2006, Day, Cleasby et al. 2009). CDK7, 
together with cyclin H and Mat1, is suggested to be responsible for the T-loop 
phosphorylation, although there are other evidences suggesting that there are other 
proline-directed kinases activating CDK4 (Bockstaele, Bisteau et al. 2009). 
1.3.2.3 Negative regulation by INK4 proteins 
The third layer of regulation is carried out by the INK4 proteins also known as CDK 
inhibitory proteins, comprising of p15, p16, p18 and p19. INK4 proteins bind to the 
ternary complex containing CDK4/6, cyclin D and Cip/Kip and distort the ATP-
binding site of CDK4/6 and change its conformation, leading to reduction in its 
binding interface to cyclin D and interaction with Cip/Kip (Russo, Tong et al. 1998, 
Jeffrey, Tong et al. 2000). p16 expression can be induced by increasing cellular age, 
presence of oncogenic RAS and presence of BRAF V600E mutation, leading to cell 
senescence or cell cycle arrest (Serrano, Lin et al. 1997, Michaloglou, Vredeveld et 
al. 2005, Ressler, Bartkova et al. 2006). TGF-beta signaling can also trigger p15 
expression, leading to cell cycle arrest (Hannon and Beach 1994). 
1.3.3 Downstream substrates of CDK4/6 
1.3.3.1 Retinoblastoma protein and E2F transcription factors 
Retinoblastoma proteins (RB1, RBL1 and RBL2) function as transcriptional 
repressor, blocking S phase entry and cell cycle when it is hypophosphorylated 
(Weinberg 1995). By directly binding to the transactivation domains of E2F 
transcription factor family, which activates transcription of genes required for S phase 
entry, the RB/E2F complex then binds to the promoters of these genes, repressing 
transcription and further inducing chromatin remodeling via recruitment of histone 
deacetylase 1 (HDAC1) (Luo, Postigo et al. 1998, Talluri and Dick 2012). Active 
CDK4/6 phosphorylates RB proteins at their N and C terminus and this possibly 
destabilizes their binding to E2F and HDAC1 and results in the disintegration of the 
transcriptional repressor complexes, freeing E2Fs to function as transcription 
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activators (Harbour, Luo et al. 1999, Burke, Deshong et al. 2010). The transcription 
activators of the E2F family are E2F1-3 and the genes transcribed by them are 
involved in DNA replication, DNA repair and DNA damage checkpoints, processes 
that are crucial in S phase (Ren, Cam et al. 2002, Bracken, Ciro et al. 2004). 
1.3.3.2 FOXM1 transcription factor 
Another major substrate of CDK4/6 is forkhead box M1 (FOXM1) which is a 
transcription activator important for G1 to S phase transition as well as G2 to M 
phase transition. Activate CDK4/6 phosphorylates FOXM1 at its N and C terminus, 
stabilizing it and preventing it from proteasomal degradation. Multiple 
phosphorylations on its C-terminal also induce FOXM1 transactivation, with more 
phosphorylation resulting in higher level of transactivation (Anders, Ke et al. 2011). 
FOXM1 phosphorylation is further regulated by other proteins such checkpoint 
kinase 2 in response to DNA damage leading to increased FOXM1 stability (Tan, 
Raychaudhuri et al. 2007) as well as phosphorylated ERK which promotes the 
nuclear translocation and transactivation of FOXM1 (Ma, Tong et al. 2005).  
FOXM1 is overexpressed in many cancers, such as ovarian cancer where high 
FOXM1 expression is associated with poor patient outcome and paclitaxel 
(microtubule-stabilizing chemodrug) resistance (Zhao, Siu et al. 2014). Specifically, 
in CRC, the 5 year survival rate for patients with high FOXM1 expression is 
significantly lower than those with low FOXM1 expression and is also correlated to 
lymph node and liver metastasis and advanced TNM stage (Chu, Zhu et al. 2012). In 
addition, in the comprehensive molecular profiling of 276 colon and rectal cancer 
tumors carried out by The Cancer Genome Altas, integrated analysis from exome 
sequencing, promoter methylation, DNA copy number alterations and mRNA and 
microRNA expression have shown elevated FOXM1 as well as MYC and E2F 
expression in almost all CRC tumors (2012). FOXM1 transcription factor is also 
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implicated in cell migration, invasion and angiogenesis, prompting the development 
of FOXM1 inhibitors (Koo, Muir et al. 2012, Halasi and Gartel 2013). 
1.3.3.3 Others CDK4/6 downstream substrates 
Other well-known substrates of CDK4/6 include SMAD2 and SMAD3 which have 
mainly roles in G1 to S phase transition (Matsuura, Denissova et al. 2004). 
Phosphorylation of SMAD2/3 by CDK4/6 prevents the SMAD proteins from 
repressing the transcription of MYC and this results in the blocking of the cytostatic 
effect of TGF-beta signaling on the cells (Chen, Kang et al. 2002, Matsuura, 
Denissova et al. 2004). 
1.3.4 Dysregulation of CDK4/6 pathway in cancer 
Alterations in CDK4/6 is rarely observed in cancer, however, mutations and changes 
in expression of other members of the CDK4/6 pathway are frequently seen. In 
colorectal cancer, CCND1 overexpression and CCND1 amplification are present in 
about 55% and 2.5% of all cases respectively (McKay, Douglas et al. 2000, 
Toncheva, Petrova et al. 2004). Aberrant methylation on CDKN2A locus resulting in 
loss of p16 protein expression is detected in 25-42% of CRC, more frequently in 
advanced CRC and may indicate poorer prognosis (Yi, Wang et al. 2001, Goto, 
Mizukami et al. 2009, Veganzones-de-Castro, Rafael-Fernandez et al. 2012).  
Amplification of HER2/ERBB2 receptors in about 20% of breast cancer and KRAS 
mutation can drive the overexpression of cyclin D1 through the RAS/MEK/ERK and 
PI3K/AKT pathways (Lenferink, Busse et al. 2001, Klein and Assoian 2008, 2012). 
In CRC, loss of APC deregulates WNT/APC/beta-catenin signaling, stimulating the 
constitutive transcription of cyclin D1 and D2 through T-cell factor and its target 
gene, CMYC respectively (Bouchard, Thieke et al. 1999, Shtutman, Zhurinsky et al. 
1999). In T-cell lymphoblastic leukemia, NOTCH1 activating mutation, which is 
present in over 50% of all cases, also drives cyclin D3 overexpression (Ferrando 
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2009, Joshi, Minter et al. 2009). With higher level of cyclin D and the loss of 
expression of negative regulator p16, CDK4/6 activity is elevated, leading to 
unregulated hyperphosphorylation of RB and FOXM1 and deregulated cell cycle 
progression.   
Mutations in RB is rarely observed in CRC but in other cancers, RB inactivation is 
commonly observed especially in small cell lung cancer where more than 90% of all 
cases exhibit RB inactivation (Burkhart and Sage 2008). This further emphasizes the 
role of CDK4/6 in promoting tumorigenesis through its role in regulating the activity 
of important tumor suppressor RB. 
1.3.5 Clinical Application of CDK4/6 in cancer 
Due to CDKs crucial role in cell cycle, there have been many inhibitors developed in 
the past decades and the first generation inhibitors are largely non-specific as they 
inhibit multiple CDKs. Flavopiridol, the most investigated CDK inhibitor, has been 
shown to inhibit CDK1/2/4/6/7/9 (Sedlacek, Czech et al. 1996, Shapiro 2006) in vitro 
but it was discontinued due to its lower than expected efficacy in clinical trials.  
Reasons behind the failure of these CDK inhibitors with low specificity could be the 
targeting of multiple important CDKs in the normal cells such as CDK1, leading to 
toxicities which prevent the drug from being used at a higher and more efficacious 
dose (Asghar, Witkiewicz et al. 2015). The lack of specificity in the earlier generation 
of CDK inhibitors prevented their use in combination therapies and there was a need 
to design more specific CDK inhibitors. 
Currently Palbociclib, a CDK4/6 small molecule kinase inhibitor, has already been 
approved by the U.S. FDA for the treatment of estrogen receptor-positive and human 
epidermal growth factor receptor-negative breast cancer together with letrozole. It 
shows high specificity for CDK4 and CDK6 with IC50 values for CDK4 and CDK6 at 
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11nM and 16nM respectively (Toogood, Harvey et al. 2005). Palbociclib competes 
with ATP for binding for the ATP-binding pocket of CDK4/6. 
Palbociclib treatment leads to sustained repression of RB phosphorylation and tumor 
regression in colorectal cancer xenografts, and also G1 arrest in breast, lung and 
colon cancer cell lines (Fry, Harvey et al. 2004). In oncogenic KRAS-driven murine 
non-small cell lung cancer model, Palbociclib was able to drastically slow down the 
tumor growth through inducing senescence response in the tumors (Puyol, Martin et 
al. 2010). LEE011, another specific CDK4/6 inhibitor, has also shown to elicit cell 
cycle arrest and senescence response in neuroblastoma (Rader, Russell et al. 2013), 
showing that CDK4/6 inhibition is indeed effective in a wide range of cancer types. 
Putative positive biomarkers of response to CDK4/6 inhibition include CCND1 
amplification/overexpression and loss of p16 (Konecny, Winterhoff et al. 2011). 
However, studies have shown that tumors still responded to CDK4/6 inhibitors even 
without the presence of positive biomarkers. More importantly is the presence of 
functional RB as absence of functioning RB predicts resistance to CDK4/6 (Fry, 
Harvey et al. 2004, Dean, Thangavel et al. 2010). CDK4/6 inhibitors are currently in 





1.4 Aims and objectives of study 
In the past decades, intensive effects have been made to find effective targeted 
therapies for KRAS mutant cancer including CRC. However, up to this point, there is 
still no treatment other the standard chemotherapy available in the clinics. Much of 
the combinatorial treatments suggested in the recent years are based on cell lines 
models where high throughput small interference RNA screenings were done to 
identify synthetic lethal genes specifically in existing KRAS mutant cell lines or 
where differential gene expression signature were obtained by comparing KRAS 
mutant and wild type cancer cell lines to identify targetable KRAS dependent 
pathways (Sarthy, Morgan-Lappe et al. 2007, Scholl, Frohling et al. 2009, Cox, Fesik 
et al. 2014). Cancer cell lines models may not accurately represent the deregulated 
expression profile in patients' tumors and this might be one of the reasons for the lack 
of efficacy of combination treatment in the clinical trials. Other synthetic lethal genes 
such as STK33 and TBK1 identified in KRAS mutant cancer cells either do not have 
their specific inhibitors or their inhibitors are still in preclinical studies (Barbie, 
Tamayo et al. 2009). Moreover, studies have also revealed the presence of KRAS 
dependency and independency in KRAS mutant cancer and found KRAS mutation to 
be an inadequate biomarker for MEK/ERK pathway activation, further increasing the 
complexity in finding a suitable treatment strategy for KRAS mutant cancer (Singh, 
Greninger et al. 2009, Yeh, Routh et al. 2009, Singh, Sweeney et al. 2012). 
Our approach is to first identify a clinically relevant KRAS dependency gene 
signature from patients-derived CRC tumors. By obtaining gene expression profile 
driven by KRAS, we can proceed to identify pathways other than the MEK/ERK 
pathway that oncogenic KRAS is dependent on. We hypothesize that by identifying 
these pathways, we can then use pharmacological tools to inhibit the pathway that 
KRAS mutant CRC are co-dependent on together with MEK/ERK pathway 
inhibition. And specifically, we hypothesized that by inhibiting the CDK4/6 and 
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MEK, the growth of KRAS dependent CRC will be impeded. In addition, this gene 
signature could be potentially used together with existing method of KRAS mutation 
detection to better predict CRC tumors that will respond to our proposed treatment 
strategy.  
Clearly, our aims are: 
1. To develop an effective treatment strategy against KRAS mutant CRC. 














2.1 Cell lines and Drug treatment 
DLD1, HCT116, HCT15, RKO, HT29, FHs74 Int and CCD841 CoN cell lines were 
obtained from American Type Culture Collection. KRAS isogenic DLD1 lines were 
obtained from Horizons Discovery. DLD1, HCT116, HCT15, RKO and HT29 were 
grown in Dulbecco’s modified Eagles’s medium (Gibco) supplemented with 10% 
fetal bovine serum (Gibco) and 5000U/ml penicillin/streptomycin (Gibco). Growth 
media for FHs 74 Int and CCD841 CoN were cultured in DMEM with additional 
supplement of 30ng/ml EGF, non-essential amino acid (Gibco), 10ug/ml insulin, 
1mM oxaloacetate and 0.5mM sodium pyruvate (Gibco). KRAS isogenic DLD1 lines 
were grown in RPMI 1640 medium (Gibco) supplemented with 10% fetal bovine 
serum and 5000U/ml penicillin/streptomycin. All cells were maintained in 75cm2 
flasks in a humidified incubator at 37°C with 5% carbon dioxide. Patient tumor 
derived spheres were grown in DMEM/Ham’s F12 (Nacalai Tesque) and 
supplemented with 1X B27 (Gibco), 0.5ug/mL Hydrocortisone, Heparin, 20ug/mL 
EGF and 20ug/mL FGF. Patient tumor derived adherent line 14S was grown in 
DMEM supplemented with 10% fetal bovine serum, 5000U/ml 
penicillin/streptomycin, 4ug/ml insulin and non-essential amino acid. 
Palbociclib and PD0325901 were obtained from Axon Medchem (Groningen, 
Netherlands) and drug treatments for all experiments were given one day after 
seeding. 1.5 x 105cells were seeded for 48 hour drug treatment for protein extraction 
as well as RNA extraction. 
2.2 Cell viability assay, Fluorescence Activated Cell Sorting 
Optimal cell seeding density was determined empirically for all cell lines by 
examining the growth of a range of seeding densities in a 96-well format. For the cell 
viabilitly assay, 1000 cells were then seeded per well 24 h before drug treatment in at 
least triplicate. Media were carefully removed before 100µl of fresh media with 
inhibitor were added to each well. To measure cell viability, 50µl of CellTiter-Glo® 
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substrate were added to each well to lyse the cells and the 96-well plate was then 
incubated at room temperature for 15 minutes inclusive of 5 minutes of shaking. Cell 
viability was then measured via chemiluminescent signals using GloMax Explorer 
(Promega). CellTiter-Glo values obtained were normalized to either the day of 
seeding (day 0) or the day of drug addition (day 1). 
For fluorescence activated cell sorting assay, 5000 cells were seeded per well in 6-
well plate with at least 3 wells per treatment condition. Media were removed with the 
addition of fresh media with inhibitors the next day and cells were treated for 7 days 
with a top-up of media and drug on day 5. Cells were harvested by trypsinization, 
washed with cold PBS and fixed with 70% ethanol for at least 1 hour. Cells were 
washed with PBS again before treating with RNase for 5 minutes. Cells were then 
stained with propidium iodide (50ug/ml) for 30 minutes, analyzed with FACScalibur 
(BD Biosciences) and quantified by CellQuest software (BD Biosciences). 
2.3 RNA extraction 
1ml Trizol added directly to lyse monolayer cells, followed by the addition of 200µL 
of chloroform and centrifugation at 12,000g to separate RNA from DNA and protein. 
Top liquid phase containing RNA was transferred to a fresh eppendorf tube with 70% 
ethanol added. RNAeasy mini kit (Qiagen) was used for RNA purification. Briefly, 
samples were transferred to columns to allow RNA binding and then subjected to 
centrifugation at 10,000rpm for 30 seconds. Columns were then washed once with 
750µL RW1 buffer and twice with 500µL RPE buffer and eluted with 35-50µL of 
nuclease free water. RNA concentration and purity were then assessed using 
Nanodrop machine 
2.4 cDNA conversion and Real time quantitative PCR 
Using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems), 
RNA samples were reverse transcribed and converted into complementary DNA 
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(cDNA). In short, 750ng of RNA were diluted in 25µL of nuclease free water and a 
reaction mixture containing 5µL of reverse transcriptase buffer, 5µL of random 
primers, 2µL of dNTP mix and 2.5µL of MultiScribe™ reverse transcriptase and 
10.5µL of nuclease-free water was added. Reaction mixture was subjected to PCR 
using thermo cycler and the protocol of 10 minutes at 25°C followed by 2 hours at 
37°C. Quantitative PCR was performed using 0.44µL of cDNA samples together with 
0.4µL of 10µM gene specific primer mix and 5µL of KAPA SYBR FAST qPCR Kits 
(Kapa Biosystems). Reaction mixture was topped up to 10µL with nuclease-free 
water, amplified and quantified with PRISM 7900 Sequence Detection System 
(Applied Biosystems). Sequences for the real time quantitative PCR primers are as 
followed: 
Gene Forward Primers 5'-3' Reverse Primers 5'-3' 
ACTB GCACAGAGCCTCGCCTT GTTGTCGACGACGAGCG 
FOXM1 AACCGCTACTTGACATTGGC GCAGTGGCTTCATCTTCC 
BUB1 ATCTCCCTGGGTAGCTTCGT CCATCAAGCCCAAGACTGAA 
PBK CAGCTGCCGGGCGTATGTGT CTCAGTCCAGAGTCTCACCGCCT 
CDCA7 GGCTTTTCAGAAAGTGAGGTGC AACTTCATCGCCACCCTGAG 
FOXM1B AGGTGTTTAAGCAGCAGAAACG GCTAGCAGCACCTTGGGGGCAA 
CDK2 ATCCGCCTGGACACTGAGAC TTGCAGCCCAGGAGGATTTC 
KIF11 CTGCCAGCAAGCTGCTTAAC CCTGGGAATGGGTCTGCTTT 
TIMELESS ATGACAGGTCTTCCAGTCGC TGGATGATCTGCTTGCGTGT 
BUB1B GCAAAGGGAAAAAGACAGCA TGCATCTGTTGAGGAAATGG 
 
2.5 Microarray Gene Expression Profiling 
Microarray hybridization was carried out using the Illumina Gene Expression 
SentrixBeadChip HumanRef-8_V2 according to the manufacturer’s protocol. In brief, 
500ng of RNA samples were reverse transcribed into cDNA and processed into 
 42 
 
double-stranded cDNA. Biotinylated cRNA was then generated from purified cDNA, 
purified and hybridized onto BeadChip. After washing, the cRNA was then bound 
with streptavidin. BeadChip was then scanned using Illumina BeadArray Reader and 
the images were processed using Illumina GenomeStudio™. The generated data was 
imported into GeneSpringGX™ (Aglient Technologies) for analysis. Signals were 
normalized to median expression and fold change were analyzed using pairwise 
comparisons to the controls (untreated samples). Median-normalized data were 
represented in log2 transformed values and were processed by Cluster and Treeview 
software to get heatmap. Illumina gene expression data of human CRC and matched 
normal controls can be found in GEOarchive under accession number GSE10972 and 
GSE74604. Gene expression for DLD1 treated with Palbociclib and PD0325901 for 
24, 48 and 72 hours can be found under accession number GSE74604. 
2.6 Synergy scoring 
To identify synergistically upregulated and downregulated genes after treatment with 
Palbociclib and PD0325901, formula previously used in (McMurray, Sampson et al. 
2008) were applied.  Let a be the expression value of a given gene after Palbociclib 
treatment, b represents the expression value for the same gene after PD0325901 
treatment and d represents the expression value for this gene after Palbociclib and 
PD0325901 combination treatment. The formula defines synergistic genes as  
𝑎+𝑏
𝑑




≤ 0.9 for downregulated genes. This 
formula was implemented after fold change 2 cut-off was applied gene expression 
data from DLD1 to obtain differentially regulated genes after treatment. 
2.7 Gene ontology analysis 
For analysis of the effect of the treatment of Palbociclib and PD0325901 on cellular 
signaling, Ingenuity Pathway Analyses (IPA) software was used. Genes that were 
differentially expressed with a fold change of 2 in any of the treatment groups as 
compared to controls were imported into IPA. Activation Z-score for predicted 
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upstream transcription factors were obtained. Enriched signaling pathways and 
diseases/biological functions were also obtained. The same analysis was repeated for 
synergistic genes using expression values of 72 hour timepoint. Results were 
exported and plotted on GraphPad.   
2.8 siRNA transfection 
SiRNA transfection was done with Lipofectamine RNAiMAX (Invitrogen) according 
to manufacturer’s protocol. Both non-targeting control, siNC, and target-specific 
siRNA were purchased from Integrated DNA Technologies. The sequences for the 
specific siRNA are as follow: KRAS siRNA: 5’-GACGATACAGCTAATTCAGAA-
3’; FOXM1 siRNA: 5’-GGACCACUUUCCCUACUUU-3’. For siRNA transfection, 
1.5µL of siRNA (20uM) and 2µL of Lipofectamine RNAiMAX were added 
separately to 100µL of OPTI-MEM (Invitrogen). After incubation at room 
temperature for 5 minutes, the two diluents were mixed and further incubated at room 
temperature for 20 minutes. The transfection reaction was then added onto cells with 
800µL of complete media. After 24 hours, transfected cells were then reseeded for 
cell viability assay or for RNA and proteins. 
2.9 Anchorage Independent colony formation assay 
3% agar mixture was prepared by heating dissolving bactoagar in PBS. Agar mixture 
was then further diluted to 0.6% using complete media and coated onto 6 wells plates. 
5000 cells in 0.3% agar mixture and seeded onto the pre-coated agar plate. 1ml of 
media or media containing drug treatment were added to each well the following day. 
After 12 days, the colonies were stained overnight with iodonitrotetrozolium chloride 





Genomic material extracted from tumor samples were amplified along the KRAS 
codon 12 and 13 region with KRAS PCR forward primer, 5’-AGGCCTGCTGAA 
AATGACTG-3’, and a biotinlyated KRAS PCR reverse primer, 5’-
[Biotin]CAAGATTTACCTCTATTG-3’. Using the Qiagen PyroMark PCR kit, two 
40 cycles of PCR were done get sufficient templates. Briefly, genomic material was 
added to reaction mixture containing 5µL of PyroMark master mix, 0.4µL of KRAS 
forward and reverse primers (5uM) and nuclease free water added to a final volume 
of 10µL. The reaction mix is subjected to PCR in a thermo cycler with the following 
program: Initialization for 15min at 95°C to activate DNA polymerase; Denaturation 
for 30sec at 94°C; Annealing of primers to single strand template for 30sec at 56°C; 
Elongation for 30sec at 72°C: repeat denaturation to elongation step for 39 cycles; 
Final elongation step for 5min at 72°C; Hold at 4°C. Agarose gel was run to semi-
quantitatively check the amount of PCR products obtained for both PCR reactions. 
To prepare for the sequencing reaction, PCR product is incubated for 30min at room 
temperature in a reaction mixture containing 40µL of binding buffer, 2µL of 
Streptavidin Sepharose beads and top up with nuclease free water to 80µL to allow 
the binding of the biotinlyated PCR products to the beads.  The KRAS sequencing 
primer (5’-TTGTGGTAGTTGGAGC-3’) is diluted using annealing buffer from 
100uM to 0.3uM and 25µL was added to the each well on the Qiagen PyroMark Q24 
plate. The PCR products bound to the beads were denatured, leaving only the 
biotinlyated single strand temple and released into the plate containing the sequencing 
primer. The mixture is then incubated at 80°C for 2min and cooled to room template 
to allow the sequencing primer to hybridize to the template. The reaction mixture is 
then placed in the machine where DNA polymerase, ATP sulfurylase, luciferase, and 
apyrase as well as their substrates adenosine 5’ phosphosulfate (APS) and luciferin 
are added. The different deoxyribonucleotide triphosphates (dNTPs) were added 
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sequentially. Incorporation of a complementary nucleotide to the template released 
pyrophosphate which is a substrate for the production of ATP from ATP sulfurylase 
reaction and the ATP produced led to the production of visible light from luciferase 
reaction. Apyrase degrades unused dNTP and ATP from the addition of the next 
dNTP. The light produced generates a peak and the height of the peak is proportional 
to the number of nucleotide incorporated, allowing for the quantification of KRAS 
mutation found on codon 12 and 23 in each tumor samples. Reaction mixtures were 
ran on Qiagen PyroMark Q24 using PyroMark Q24 Gold Q24 Reagents Kits and data 
was analyzed using the PyroMark Q24 software. 
2.11 Antibodies and Immunoblotting 
Antibodies against the following proteins were obtained from Cell Signaling 
Technology (Danvers,MA, USA) and used at the indicated dilution: RB (4H1) #9309 
(1:2000), P-RB Ser780 #9307 (1:1000), P-p44/22 MAPK (ERK1/2) Thr202/Tyr204 
#9101 (1:1000), Total p44/22 MAPK (ERK1/2) #9102 (1:2000), c-Myc #9402 
(1:2000) and pFOXO3A Ser253 #9466 (1:1000). Antibodies to the following proteins 
were obtained from Santa Cruz Biotechnologies (Santa Cruz, CA, USA): FOXM1 
(A11) #sc-271746 (1:500), Cyclin B1 (GNS1) #sc-245 (1:500), E2F1(C-20) #sc-193 
(1:1000), E2F4 (A-20) #sc-1082 (1:1000) and Cyclin D1 (HD11) #sc-246 (1:1000). 
Beta actin antibody was obtained from Sigma-Aldrich and used at the dilution of 
1:200,000. 
For immunoblotting, cells were trypsinized and washed in PBS before being 
subjected to lysis using radioimmunoprecipitation assay lysis buffer (50mM Tris-HCl 
pH7.4, 1mM EDTA, 150mM NaCl, 1% Igepal CA630, 0.5% sodium deoxycholate, 
1mM Na2VO4, 20mM NaF, 1mM PMSF and complete protease inhibitor (Roche)).  
Samples were incubated on ice for 30 minutes and subjected to sonication before 
centrifugation at 13200rpm for 15 minutes at 4°C. Supernatant was transferred into 
fresh tubes and protein concentration was estimated using the BioRad Bradford dye 
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with known BSA concentration as standards and measured using Tecan Xfluor™ 
software.  
To obtain protein lysates from xenograft studies, tumors were lysed in the same 
buffer with the use of the Tissuelyser II (Qiagen) at the frequency of 30 
rounds/second for 45 seconds for 3 cycles. The lysates were then subjected to the 
same downstream process as monolayer cultured cells. 
Protein samples (30µg) were separated by 8% or 12% SDS-PAGE gel and 
subsequently transferred onto PVDF membrane (Millipore) using Trans-Blot SD 
Semi-Dry transfer cell (Bio-Rad). Membranes with immobilized proteins were 
blocked with 5% BSA (Sigma) or 5% non-fat milk (Bio-Rad) for at least 2 hour 
followed by primary antibodies for 1 hour to overnight incubation depending on the 
specific antibodies and HRP-conjugated secondary antibodies for 1 hour. 
Membrances were incubated with chemiluminescent Supersignal®  West  Femto 
maximum sensitivity substrate (Thermo Scientific) and signals were detected using 
ChemiDoc™ MP imaging systems (Biorad) with Imagelab software. 
2.12 In Vivo Treatment Studies 
DLD1 and RKO xenografts were generated via the injection of 3 x 106 cells with 
Matrigel in a ratio of 1:1 into the flank of 4-8 week old female NOD/SCID mice. 
Mice were randomized to 4 treatment groups once the tumors reached the average 
size of 100mm3. Palbociclib were administered daily at 35mg/kg for DLD1 
xenografts and at 50mg/kg for RKO xenografts via oral gavage. PD0325901 were 
administered daily for 5 days at 20mg/kg via oral gavage. Vehicle for Palbociclib was 
PBS and for PD0325901 was 0.5% hydropropylmethylcellulose, 0.2% Tween-80 and 
5% DMSO.  Tumor volume was measured by electronic caliper twice a week and 
calculated with the following formula: Length x (Width2) x 0.5. Palbociclib (CT-
PD2991) and PD0325901 (CT-PD03) for in vivo use were obtained from ChemieTek 
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(Indianapolis, IN). Mice were obtained from Invivos (Singapore) and housed in 
Biological Resource Centre. 
2.13 Study Approval 
All animal studies were performed in compliance with protocols approved by 
Biopolis Institutional Animal Care and Use Committee of Singapore. Human CRC 
tissue DNA and RNA samples were originally obtained from Singapore Tissue 
Network and National University of Singapore (NUS) using protocols approved by 
Institutional Review Board of NUS. Informed consent was obtained from each 
individual who provided the tissues. 
2.14 Statistical analyses  
In-vitro experiments were repeated at least three times and data are reported as 
mean+s.e.m. Statistical significances were assessed by two-tailed Student’s using 
Student’s t-test, one-way or two-way analysis of variance for multiple group 
comparisons using GraphPad Prism 6 software. P≤0.05 was considered significant. 
2.15 Computational Modeling 
This portion of the work was done by Fan Zhang and Dr Zheng Jie from Nanyang 
Technological University. 
Network construction 
More genes were observed to be down-regulated synergistically as compared to the 
up-regulated ones, we chose to focus on the down-regulated genes and synergistically 
downregulated genes were selected (23 genes). Next, from the UCSC_TFBS [1] 
database, transcription factors that are able to transcriptionally regulate these 23 genes 
were identified. Next, signaling pathways containing the drug targets (i.e., CDK4/6 
and MEK) and related neighbors were extracted from GeneGoMetaCore [2]. The 
transcription factors that are not downstream of the extracted signaling pathways 
were excluded because their activities are unlikely to be perturbed by the drugs. 
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Altogether, the network constructed is composed of 11 signaling proteins, 23 
transcription factors and 23 synergistically downregulated genes. In total, there are 
122 edges in the network: 14 edges among signaling proteins with the interaction type 
of phosphorylation; 35 edges leading from signaling proteins to transcription factors 
with interaction type also phosphorylation; and 73 edges representing transcription 
factors transcriptionally regulating the targeted genes.  
Network Component Analysis 
To reversely derive the activities of the transcription factors from the gene expression 
profile, Network Component Analysis (NCA) [3, 4] was employed. NCA considers 
the biochemical reactions of the network to deduce the activity profiles of 
transcription factors using temporal gene expression data and relationships between 
transcription factors and their respective targeted genes. The gene regulatory network 
is represented as a “bipartite network model”, which requires time-series gene 
expression data and interaction relationships between transcription factors and target 
genes (in the form of a connectivity matrix) as the input data. Given the time-series 
gene expression data [E]g×t and the connectivity matrix [C]g×f, where g, t and f 
indicate the numbers of genes, time points and transcription factors, respectively. 
NCA is able to obtain the activities of transcription factors over time [A]f×t, by 
decomposing the matrix [E] in the following equation into two matrices [C] and [A]. 
[𝐸]𝑔×𝑡 = [𝐶]𝑔×𝑓[𝐴]𝑓×𝑡 
Here matrix [E] contains the expression profiles of the 23 synergistically down-
regulated genes at 3 time points (i.e., 24h, 48h and 72h), and [C] is the prior 
knowledge of the regulatory relationships between the transcription factors and genes 
obtained from UCSC_TFBS and GeneGoMetaCore (i.e., the 73 edges, which 
represent relations of transcriptional regulation, in the aforementioned network). 
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According to [4], the elements in the connectivity matrix [C] for all the transcription 
factors that have no connection with respective genes were set to zero; the rest of the 
elements were then assigned to an arbitrary value. Next, the columns of [C] were 
normalized such that the mean absolute value of the non-zero elements in the matrix 
for each column would be equal to the number of controlled genes. For example, if 
the i-th transcription factor regulates j genes, the mean absolute value of the non-zero 





























3.1 Identification of a KRAS mutation associated gene signature showed 
enrichment for cell cycle and mitosis in colorectal tumors and predict an 
dependency for CDK4/6 activity 
In search of an effective treatment strategy for KRAS mutant colorectal cancer, many 
groups have intensely studied the molecular signaling in  KRAS mutant colorectal 
cancer and came up with combinatorial treatment strategies by inhibiting both MEK 
together the function of AKT (She, Halilovic et al. 2010), IGFR1 (Ebi, Corcoran et al. 
2011), HER3 (Human Epidermal Growth Factor receptor 3) (Turke, Song et al. 
2012), BCL-2/BCL-xL/MCL1 (B-cell lymphoma 2/xL/Myeloid cell leukemia 
1)(Corcoran, Cheng et al. 2013) or RAF (Lamba, Russo et al. 2014). These treatment 
strategies were proposed through the use of KRAS isogenic cell lines or different 
colorectal cancer cell line models with different KRAS mutation status to identify 
pathways that are important for the survival of KRAS mutant cells especially in the 
presence of MEK inhibition or through the differential gene expression between  
KRAS mutant and wild type cancer cell. These models were based on in vitro cell 
lines model as the heterogeneity in patient CRC tumors, due to presence of sub-
clones driven by different oncogenic mutations, had hindered the identification of 
gene expression driven by aberrant KRAS signaling. 
Here in our studies, to identify a KRAS dependent colorectal cancer gene expression, 
we performed gene expression profiling on 55 colorectal tumors using Illumina 24K 
human BeadArray-V3 as well as pyrosequencing of KRAS at codon 12 and 13 to 
quantify the level of KRAS mutation in the tumors in order to overcome the issue of 
tumor intraheterogeneity. We stratified the tumors into KRAS wildtype (<10% of 
KRAS mutation), low KRAS mutation (10-40%) and high KRAS mutation group 
(>40%) (Figure 3.1A) and proposed that the high KRAS mutation tumors contain 
mainly KRAS mutant cells whereas KRAS wildtype or low KRAS mutation tumors 
consists of mainly KRAS wild type cells. Supervised gene clustering analysis of these 
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tumors revealed 97 genes were significantly correlated with KRAS mutation (P<0.05) 
with56 genes meeting the cutoff of Pearson correlation of <-0.3 or >0.3 (Figure 
3.1B). 34and 22 genes were differentially upregulated and downregulated 
respectively in the high KRAS mutation group. In a recent study, polycomb protein 
EZH2, a methyltransferase, has been positively associated with KRAS mutation in 
lung cancer and inhibiting EZH2 can sensitize KRAS mutant cells to chemotherapy 
(Riquelme, Behrens et al. 2015). Among the downregulated genes associated with 
KRAS mutation, FBXO32, an EZH2-repressed apoptotic target, when repressed by 
EZH2, has been associated with chemoresistance, suggesting that EZH2 functions 
similarly in KRAS mutant CRC (Tan, Yang et al. 2007, Wu, Lee et al. 2011). We 









Figure 3.1 Identification of a KRAS associated Gene Signature in Colorectal 
Cancer 
A. Stratification of colorectal tumors in groups according to the level of 
KRAS mutation (in codon G12 and G13) detected via pyrosequencing. 
KRAS Wildtype consists of tumors with less than 10% KRAS mutation; 
Low KRAS mutation for those between 10-40% mutation; High KRAS 
mutation for tumors with more than 40% mutation detected. 
B. Heatmap showing the 56 genes which expression correlates with level of 
KRAS mutation. Pearson correlation ≤-0.3 or ≥0.3 with a p-value ≤0.05 
were used as a cut-off. The 34 upregulated genes (in red brackets) were 
then termed as the KRAS dependency gene signature. Colored scale bar 
represents log2 transformed values. 
C. Heatmap showing expression of genes which are markers for various cell 
types found in the tumor microenvironment that could possibly contribute 
to the tumor gene expression profile and none of the genes were found to 
be significantly differentially expressed in any of the group using one way 
ANOVA test. CDH1, EPCAM and KRT20 were used as markers for 
epithelial cells; CD2, CD19 and PTPRC for leukocytes; CDH5, ENG and 
VWR for endothelial cells; DCN, PDPN and FAP for fibroblasts. Colored 















To counter the possibility that the differential gene expression seen in the three group 
was due to different level of stroma content in the tumor sampled, we checked the 
expression of markers that were previously used to identify the various cell types 
(Calon, Lonardo et al. 2015): CDH1, EPCAM and KRT20 for epithelial cells; CD12, 
CD19 and PTPRC for leukocytes; CDH5, ENG and VWF for endothelial cells; DCN, 
PDPN and FAP for fibroblasts. Solid tumors do contain cells of other origins as 
mentioned above (Egeblad, Nakasone et al. 2010)and these cells types though found 
in much less quantity than the tumor cells, may skew the gene expression of the 
tumors, especially the tumors in the low KRAS mutation group. Thus, it was 
important to show that the differentially lower expression of KRAS dependency gene 
signature in the low KRAS mutation group was not due to the increased presence of 
other non-tumor cells ‘diluting’ the expression from the tumor cells. None of the 
markers were found to be significantly different in any group, strengthening our 
Figure 3.2 KRAS dependency gene signature highly associated with cell cycle 
and mitosis processes  
A. Top 15 enriched gene ontology biological processes from Molecular 
Signature Database which significant overlaps were observed with the 34 
genes from the KRAS dependency gene signature. Majority of the top 
enriched gene ontology are related to cell cycle and mitotic processes. 
B. The top upstream regulators of the 97 genes which expression were 
significantly correlated with KRAS mutation (P<0.05). CDKN1A, 




findings that the upregulation of the gene signature in the high KRAS mutation group 
is due to KRAS mutation (Figure 3.1C). 
To gain further insights, we used the Molecular Signature Database and found 
significant overlaps of the upregulated KRAS associated genes with gene sets 
involved in cell cycle and mitosis processes (Figure 3.2A). We also performed 
Ingenuity Pathway Analysis (IPA) on the 97 genes significantly correlated with 
KRAS mutation level and p21CIP/WAF or CDKN1A and Retinoblastoma protein, RB, 
were predicted to be top upstream regulators (Figure 3.2B). It is interesting to note 
that both p21 and RB regulate the cell cycle checkpoint from G1 to S phase; p21 
mainly inhibits CDK2 activity which is required for the phosphorylation of RB for 
the subsequent release and activation of E2F-regulated gene transcription program 
and other than CDK2, CDK4/6-cyclin D complex is the other important regulator of 
RB activity. Another top upstream regulator, SMARCB1 (Figure 3.2B), though not 
directly involved in G1 phase of cell cycle, is a core component of the SWI/SNF 
nucleosome remodeling complex which modulates the transcription of lineage-
specific genes as well as represses genes involved proliferation such as MYC, 
CCNB1 and CDK1(Wilson and Roberts 2011), which are required for the mitotic 
phase. In addition, FOXM1, a transcription factor regulating cell cycle and mitotic 
genes is also upregulated in the high KRAS mutant tumors and it is activated by 
CDK4/6 (Anders, Ke et al. 2011) and phosphorylated ERK (Ma, Tong et al. 2005). 
Thus these findings suggest that the KRAS dependency gene signature identified in 
high KRAS mutation tumors showed elevated cell cycle and mitosis processes, likely 
through the abrogation of the G1 checkpoint. 
In KRAS mutant cells, it is known that the RAS/MEK/ERK pathway is constitutively 
activated, leading to increased proliferation and cell survival. However, single MEK 
inhibitor has shown no clinical efficacy in KRAS mutant cancers. Here, we 
hypothesize by looking at the transcriptional output of the high KRAS mutation 
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group that the KRAS mutation not only upregulates the MEK/ERK signaling but also 
dysregulates G1 checkpoint to drive tumorigenesis and we proposes that by co-
inhibiting the CDK4/6 pathway and MEK/ERK pathway, we can better target KRAS 




3.2 CDK4/6 inhibition sensitizes specifically KRAS-dependent colorectal cancer 
cells to MEK inhibition 
Previous studies on various CDK4/6 inhibitors, including Palbociclib, have shown 
that a wild type retinoblastoma status and a low expression of p16 predicts the best 
response to CDK4/6 inhibition in ovarian cancers (Konecny, Winterhoff et al. 2011), 
breast cancers (Dean, Thangavel et al. 2010) and glioma (Wiedemeyer, Dunn et al. 
2010). Using datasets on cBioPortal (Cerami, Gao et al. 2012, Gao, Aksoy et al. 
2013), we observed that the alteration frequency of RB1 in colorectal cancer is one of 
the lowest (Table 3.1, Figure 3.3A), suggesting that in colorectal cancer RB is mostly 
wild type and functional. To evaluate the activity of CDK4/6 activity in colorectal 
cancer, we downloaded the Kaiser Colon (Kaiser, Park et al. 2007) and TCGA 
Colorectal (2012) dataset from Oncomine and checked the expression of cyclin D1 
(CCND1) and CDK4 and found both proteins significantly upregulated in colorectal 
tumors as compared to normal colon tissue (Figure 3.3B-C). These evidence, 
combined with prior reports on 40-50% of CRC exhibiting aberrant methylation on 
p16 (Guan, Fu et al. 1999, Goto, Mizukami et al. 2009), showed that the CDK4/6 
pathway is frequently activated in colorectal cancer and the presence of positive 



























Figure 3.3 Positive indicators of response to CDK4/6 inhibition present in 
colorectal cancer 
A. Low alteration frequency of RB1 observed in colorectal cancer 
highlighted in red. Breast cancer, lung cancer and melanoma also showed 
very low level of RB alteration and CDK4/6 inhibitors are either in 
clinical use or in clinical trials for these cancer types. Dataset were 
obtained and analyzed in cBioPortal.  
B. Expression of CCND1 and CDK4 observed to be significantly higher in 
the colorectal cancer as compared to normal colon tissue in the Kaiser 
Colon dataset 
C. Expression of CCND1 and CDK4 observed to be significantly higher in 






To evaluate if inhibiting CDK4/6 pathway is able to sensitize KRAS mutant 
colorectal cancer to MEK inhibition, we first characterize the EC50 value of 
Palbociclib, a first-in-class CDK4/6 inhibitor, in 3 KRAS mutant CRC lines, DLD1, 
HCT116 and HCT15, as well as RKO, a BRAF V600E mutant line and found their 
EC50 value of Palbociclib in the micro molar scale. We then compared the dose 
response of MEK inhibitor, PD0325901, in the presence or absence of a fixed 
concentration of 1µM CDK4/6 inhibitor and found that in DLD1 and HCT116, the 
addition of CDK4/6 inhibitor led to an significant increase in MEK inhibitor 
sensitivity (7.69-fold and 11.9-fold reduction in EC50 of PD0325901 in DLD1 and 
HCT116 respectively) (Figure 3.4A). In HCT15, however, CDK4/6 inhibition did not 
significantly reduce its EC50 of PD0325901 (1.95-fold reduction) (Figure 3.4C). In 
the recent years, there have been findings that identified the phenomenon of KRAS 
independence, specifically cancer cells with KRAS mutations but upon KRAS 
knockdown or knockout, no significance decrease in cell viability were observed in 
these cells. These KRAS independent cells may have KRAS mutation but are no 
longer dependent on KRAS for growth and survival. KRAS mutation may be one of 
the key oncogenic drivers in many cancers but as cancer progresses, more mutations 
are acquired and KRAS mutation may be rendered dispensable. Not surprisingly, 
HCT15 has been found to be KRAS-independent (Scholl, Frohling et al. 2009), 
despite having a KRAS mutation, and a validation was done by knocking down 
KRAS, showing that colony formation ability of HCT15 was not affected in 
anchorage independent growth conditions (Figure 3.5). However, for KRAS 
dependent DLD1 and HCT116, the number of colony formed in soft agar condition 
were greatly reduced (Figure 3.5). This suggests that the effect of CDK4/6 inhibition 
on sensitizing cells to MEK inhibition required the cells to be dependent on KRAS.  
To further investigate if this effect of CDK4/6 inhibition sensitizing cells to MEK 
inhibition is unique to KRAS dependent cells, we also tested on BRAF mutant cells. 
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BRAF mutant cancer cells have shown to have elevated ERK activation and are 
highly dependent on the MAPK signaling, by doing this experiment, we can 
determine if this sensitization effect is also applicable on cells that are dependent 
MAPK signaling but do not have KRAS mutation. RKO, a BRAF V600E mutant 
CRC line, also showed similar increased sensitivity to MEK inhibitor after CDK4/6 
inhibition (5.48 fold reduction) (Figure 3.4B), suggesting that a dependence on the 
RAS-MAPK signaling pathway is required for MEK inhibition sensitization via 
CDK4/6 inhibition. 
To study the response of the normal colon epithelial cells to the addition of CDK4/6 
inhibitor, we repeated the same experiment on FHs 74 Int, a small intestinal epithelial 
cell line and CCD 841CoN, a normal colon cell line and observed a significant 
decrease in sensitivity to MEK inhibition in the presence of CDK4/6 inhibitor (Figure 
3.4D). This seems to suggest that CDK4/6 inhibition could reduce the toxic effect 











Figure 3.4 CDK4/6 inhibition specifically increases KRAS dependent/BRAF 
mutant CRC sensitivity to MEK inhibitor 
A. Addition of 1μM Palbociclib increased sensitivity to PD0325901 in 
KRAS-dependent CRC, DLD1 and HCT116 as seen through reduction in 
PD0325901 EC50. Assay was measured using CellTiter-Glo. 
B. Addition of 1μM Palbociclib also increased sensitivity to PD0325901 in 
BRAF mutant CRC, RKO. 
C. In KRAS-independent HCT15, addition of 1μM Palbociclib only showed 
insignificant increase in sensitivity to PD0325901.  
D. In normal colon epithelial cells, FHs 74 Int and CCD 841 CoN, addition 
of 1μM Palbociclib reduced sensitivity to PD0325901 as seen in the 
increase in PD0325901 EC50. 
Two way ANOVA used for statistical analysis of interaction between 


















Figure 3.5 KRAS knockdown reveals KRAS dependency in DLD1 and 
HCT116 and KRAS independency in HCT15 
(Left) Knockdown of KRAS carried out using short interfering RNA specific to 
KRAS led to reduction of colony formation in anchorage independent soft agar 
conditions for DLD1 and HCT116 (grey bars) as compared to the knockdown 
using non-targeting siNC (black bars). (Right) No significant reduction in colony 
formation was observed in HCT15. Unpaired Student T-test was used. ****P-




3.3 Pharmacological inhibition of CDK4/6 and MEK reduces cell viability in 
KRAS dependent and BRAF mutant colorectal cancer cells 
Based on our findings that the addition of CDK4/6 inhibitor is able to sensitize the 
KRAS dependent and BRAF mutant CRC lines to MEK inhibition, we proceeded to 
investigate the effect of combining the two inhibitors on cellular viability. Treatment 
of the cells was carried out using fixed concentration of Palbociclib and PD0325901, 
either alone or in combination over the course of 9 days and we monitored their 
viability via the level of ATP detected. The combination of CDK4/6 and MEK 
inhibitors led to a drastic decrease in cell proliferation when compared to single 
treatment of either inhibitor only in KRAS-dependent (DLD1 and HCT116) (Figure 
3.6A) and BRAF mutant (RKO and HT29) (Figure 3.6B) but this was not observed in 
KRAS-independent HCT15 (Figure 3.6C). Similarly in the normal colon epithelial 
cells, no synergistic or additive growth inhibitory effect were seen when the cells 
were treated with the combination treatment (Figure 3.6D). 
 
Figure 3.6 Increased reduction in cell viability in Palbociclib and PD0325901 
combination treatment in KRAS-dependent and BRAF mutant CRC 
(A-D) Growth inhibition response to treatment of Palbociclib and PD0325901 
either alone or in combination. Top up of fresh media and drug on day 5. Relative 
viability measured by CellTiter-Glo and compared to Day 1 untreated control. 
Concentrations used are as follow:  
A. KRAS Dependent:DLD1 (1µM Palb, 2µM PD); HCT116 (1µM Palb, 
0.1µM PD) 
B. BRAF Mutant: RKO (1µM Palb, 1µM PD); HT-29 (1µM Palb, 0.05µM 
PD); 
C. KRAS Independent: HCT15 (1µM Palb, 1µM PD) 
D. Normal colon epithelial: FHs 74 Int and CCD 841 CoN (2µM Palb, 2µM 
PD) 










We also evaluated the colony formation ability of the different cell lines after 
treatment in 2-dimensional (2D) monolayer and 3-dimensional (3D) anchorage-
independent soft agar conditions. After exposure to CDK4/6, MEK or the 
combination of both inhibitors for 12 days, the cells were stained with crystal violet 
for the 2D culture for visualization and for the soft agar culture, cells were stained 
with iodonitrotetrazolium chloride for quantification.  Only in the KRAS-dependent 
or BRAF mutant cells, the combination treatment completely eradicated colony 
formation in monolayer and anchorage-independent growth conditions (Figure 3.7A-
B). No substantial inhibitory effect was observed for KRAS-independent HCT15 
(Figure 3.7C).  These finding are consistent with earlier findings in Figure 3.4 where 
CDK4/6 inhibitor sensitized only the KRAS-dependent and BRAF-mutant cancer 
cells to MEK inhibition.  
Furthermore, we also showed that treatment with the two inhibitors led to significant 
increase in apoptosis when compared to single inhibitor treatment as indicated by the 
Sub-G1 population in HCT116 and RKO but not in HCT15 as well as the normal 
colon epithelial lines (Figure 3.8). In DLD1, combination treatment did not 
significantly increased apoptosis as compared to Palbociclib-treated cells but increase 
was significant when compared to PD0325901-treated cells. Moreover in the normal 
epithelial lines, we observed that there was no significant difference in the level of 
apoptosis between untreated cells and cells treated with the combination treatment, 
once again suggesting that the combined inhibition of CDK4/6 and MAPK pathway 
does not cause toxicity in normal non-cancerous cells. All in all, these data put 
together demonstrated that pharmacological inhibition of CDK4/6 and MEK in 
combination greatly reduced cell viability as compared to single inhibitor treatment 







Figure 3.7 Colony formation after combination treatment with Palbociclib 
and PD0325901 in 2D monolayer culture and anchorage-independent soft 
agar inhibited in KRAS-dependent and BRAF Mutant CRC only. 
A. Combination treatment with CDK4/6 and MEK inhibitors for 12 days in 
KRAS dependent DLD1 and HCT116 led to complete inhibition of colony 
formation in 2D monolayer condition as shown in the images. 
Combination treatment also led to an almost complete reduction in 
number of colonies formed in soft agar. 
B. Similar to (A), combination treatment in BRAF Mutant RKO and HT29 
led to reduction in colony formation in both 2D monolayer and soft agar 
conditions. 
C. Combination treatment in KRAS independent HCT15 did not lead to as 
marked reduction in colony formation as seen in the KRAS dependent and 
BRAF mutant in both 2D monolayer and soft agar conditions. 

















Figure 3.8 Significant induction of apoptosis in KRAS Dependent and BRAF 
Mutant CRC with combination treatment of Palbociclib and PD0325901. 
Significant increase of cell death was observed in the combination treated group 
over single inhibitor treated group in KRAS dependent and BRAF mutant CRC 
only. Percentage of apoptotic cells as indicated by sub G1 phase after 7 days 
treatment with Palbociclib, PD0325901 or both inhibitors as quantified by 
fluorescence-activated cell sorting (FACS) analysis. Concentrations used are as 
followed: DLD1 (2µM Palb, 2µM PD); HCT116 (2µM Palb, 0.1µM PD); RKO 
(1µM Palb, 1µM PD); HCT15 (1µM Palb, 1µM PD); FHs 74 Int and CCD 841 
CoN (2µM Palb, 2µM PD). Statistical analysis was done using paired Student’s T-
test. * indicates p value <0.05. 




3.4 KRAS mutant isogenic colorectal cancer line are more sensitive to 
pharmacological inhibition of CDK4/6 and MEK 
To specifically study the effect of the combination treatment on KRAS isogenic cell 
lines (cell lines with genetically identical background other than their KRAS mutation 
status), we tested the combination treatment versus single treatment in DLD1 KRAS 
isogenic cell line. Parental DLD1 is a heterozygous KRAS mutant, with one wild type 
KRAS allele and one mutated KRAS allele at codon 13, G13D. Using Horizon 
GENESISTM gene editing technology which enables precision genome editing down 
to single base pair resolution, knockout of either the KRAS wild type allele or the 
KRAS mutant G13D allele was done in parental DLD1 cells, generating DLD1 
KRAS wildtype only cells, (KRAS WT) and DLD1 KRAS mutant G13D only cells 
(KRAS G13D) respectively (Figure 3.9A). The knockout was done using an 
adenoviral associated vector by homologous recombination resulting in isogenic cell 
lines, each containing one allele of KRAS. 
We first characterized these commercially obtained cell lines and found that DLD1 
KRAS WT cells grew slower and were unable to grow in anchorage independent 
condition (Figure 3.9B) which was not surprising as mutated KRAS is known to 
transform normal cells, making them more tumorigenic. Functionally, DLD1 KRAS 
wild type cells also expressed lower levels of phosphorylated ERK in low serum 
(0.1%) and high serum (10%) conditions (Figure 3.9C), suggesting that after KRAS 
mutant knockout, the activity of the RAS/MEK/ERK pathway is decreased and no 
longer constitutively active. We then tested the combined treatment of CDK4/6 and 
MEK inhibitors on parental, KRAS WT and KRAS G13D DLD1 and found short 
term treatment up to 5 days had similar effect on all three lines (Figure 3.10A). After 
5 days, however, we observed a differential effect of the combination treatment on 
DLD-1 KRAS WT. DLD-1 KRAS WT under the combination treatment grew at a 
faster rate as compared to control and the single treatment whereas, the combination 
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treated Parental and KRAS G13D continued to display slower growth as compared 
the single treated cells (Figure 3.10B). Notably, DLD1 KRAS G13D under 
combination treatment showed negative growth at day 7 and 11 compared to day 5, 
suggesting that there might be cell death occurring. From this data, we showed that 
colorectal cancer cells with KRAS mutation are more sensitive to the combined 











Figure 3.9 Presence of KRAS mutation in DLD1 KRAS isogenic cell lines 
determines cells’ ability to grow in anchorage independent conditions. 
A. Sequencing results of the three DLD1 KRAS isogenic cell lines, showing 
in DLD1 parental cells, there are both KRAS wild type and KRAS 
mutation at codon 13, DLD1 KRAS WT where there is only KRAS wild 
type and DLD1 KRAS G13D where only KRAS mutation is present. 
B. DLD1 KRAS wild type cells were unable to form colonies in anchorage 
independent soft agar condition unlike DLD1 Parental and KRAS G13D 
which have the mutant KRAS allele and therefore still able to form 
colonies. 
C. DLD1 KRAS wild type cells expressed lower levels of phosphorylated 
ERK as compared to isogenic DLD1 lines with KRAS mutant in both 



















Figure 3.10 Greatest inhibition in proliferation seen in DLD1 KRAS G13D 
mutant treated with Palbociclib and PD0325901 with longer duration of 
treatment. 
A. No differential growth rate was observed in the three DLD1 KRAS 
isogenic cell lines treated with Palbociclib, PD0325901 or both. 
Readings from day 0 to 5 were measured using CellTiter-Glo and were 
plotted relative to day 0 and then log2 transformed. 
B. Greatest reduction in proliferation observed in KRAS G13D mutant from 
Day 5 treatment onwards. Readings from day 5 to 11 were measured 
using CellTiter-Glo and were plotted relative to day 5 and then log2 
transformed. 




3.5 Combination treatment of CDK4/6 and MEK inhibitors converge to 
downregulate KRAS associated gene signature 
To better understand the reason behind the effectiveness of the combined inhibition 
of CDK4/6 and MEK, we aimed to identify the possible mediators in the combination 
treatment. To this end, we performed a microarray analysis on DLD1 treated with 
Palbociclib or PD0325901 alone or in combination for 24h, 48h and 72h with 
Illumina 24K human BeadArray-V3 and we analyzed the data output as shown in 









Figure 3.11 Diagram illustrating the analysis of microarray data to identify 
mediators of the combined inhibition of CDK4/6 and MEK. 
Microarray analysis was performed on DLD1-treated with Palbociclib, 
PD0325901 or combination of both at time points of 24, 48 and 72 hour. IPA 
analysis was performed with 1805 genes (cutoff of fold change ≥2) and top 
regulated functions and upstream regulators were predicted. 207 genes 
synergistically regulated by the combination treatment (in at least 1 time point) 
were further identified and IPA and computation modeling were used to predict 
upstream regulators and activity of predicted transcription factor. Through these 
prediction methods, possible mediators behind the effectiveness of the combined 
inhibition of CDK4/6 and MAPK pathways can then be identified. Colored scale 
bars in heatmaps represent log2 transformed values. 
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Using Genespring, 1805 genes were found to have a fold change of at least 2 in their 
expression in one or more treatment groups (Figure 3.11 centre). We observed the 
expression of some genes were obviously very much more elevated or reduced upon 
combination treatment and proceeded to use a synergy scoring method previously 
used by McMurray et al. (McMurray, Sampson et al. 2008) to identify these genes. 
Since these genes were synergistically regulated by the combination treatment, it is 
likely that these genes are under regulation of both the CDK4/6 and MEK pathways, 
rather than just one pathway and the changes in the expression of these synergistic 
genes is possibly crucial to the effectiveness of the combination treatment. 50 
synergistically upregulated and 157 synergistically downregulated genes were found 
(Figure 3.11 right).  
The 2 gene set were then input into Ingenuity Pathway Analysis to predict potential 
upstream regulator of these genes. In the first gene set of 1805 differentially regulated 
genes of at least fold change 2, at the 48h and 72h treatment time points, FOXM1, 
MYC and E2F1 were observed to have incremental decrease in their activation z-
score in the combination treated samples as compared to the single treatment samples 
(Figure 3.12A). Activation z-score is the prediction of the activity of the 
transcriptional regulators after considering the number of target genes and their 
expression directional changes in the data set input that correspond to the curated 
target genes in the IPA database. The second dataset using the expression of the 207 
synergistic genes after 72h combination treatment also revealed the E2F1 and 
FOXM1 as the transcription factors with the most downregulated activation z-score 
(Figure 3.12B). TBX2 was not considered to be as important as it did not show 
incremental decrease in predicted activity after combination treatment so it is 
probable that the changes in its target genes were similar in both single and 
combination treatment (Figure 3.12A). There was also an increase in activation z-
score in tumor suppressors CDKN2A, SMARCB1 and RB1, suggesting that their 
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target genes might be repressed by the combination treatment (Figure 3.12A).  In 
addition, RB1 and SMARCB1 were also the predicted upstream regulators of genes 
correlated to KRAS mutation shown in Figure 3.2B, an indication that the 
combination treatment may be specifically targeting the KRAS dependency gene 
signature identified. Functions related to proliferation of cancer cells, DNA repair and 
mitosis were also predicted to be more downregulated in combination treatment and 
functions relating to apoptosis of cancer cell lines were predicted to be more 
upregulated by the combination treatment (Figure 3.13).  
 
Figure 3.12 Top predicted upstream regulators, including FOXM1, E2F1 and 
MYC, related to cell cycle and mitosis  
A. FOXM1, E2F1 and MYC were observed in top predicted upstream 
regulators showing greater decrease in activation z-score in combination 
treatment at 48 and 72h time point in IPA analysis using 1805 
differentially regulated genes. 
B. Using 207 genes synergistically regulated by combination treatment and 
their expression at 72h time point under combination treatment, E2F1 and 














Figure 3.13 Proliferation and cell cycle processes predicted to be 
downregulated and apoptosis to be upregulated after combined treatment of 
Palbociclib and PD0325901.  
Cellular functions related to proliferation, cell cycle, mitosis and DNA repair were 
predicted to be more downregulated in the combination treatment of Palbociclib 
and PD0325901 after 72 hour treatment. Apoptosis of tumor cell lines was 
predicted to be upregulated in the same treatment conditions in IPA analysis. 
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Computational modeling was also carried out to simulate the inhibition of CDK4/6 
and MEK pathway and using the expression of the 157 synergistically downregulated 
genes, the mathematical algorithm included the known transcription factors in 
existing literature and predicted their activity at each time point for each of the 
treatment group. A simplified network of the prediction modeling is shown in Figure 
3.14B where some of the known downstream transcription factors of CDK4/6 and 
MEK/ERK pathway are shown.  Figure 3.14A showed FOXM1 activity was also 
predicted to be synergistically reduced after combination treatment among other 
transcription factors as well. All the bioinformatics and computational data together 







Figure 3.14 Computational simulation predicts involvement of potential 
downstream mediators including FOXM1 and E2F1 in combined CDK4/6 
and MEK inhibition  
A. Activity of transcription factors as predicted by the computational 
simulation of CDK4/6 and MEK inhibition. FOXM1, E2F1, FOXO3 and 
CREB showed synergistic reduction of activity under combination 
inhibition as compared to single inhibition. E2F4 showed synergistic 
increase in activity under combination inhibition but no synergistic 
increase or decrease was observed in ER activity. Expression of 157 
synergistically downregulated genes together with known downstream 
transcription factors of CDK4/6 and MEK pathways were used in the 
prediction. 
B. Simplified network of known signaling proteins (pink nodes) in the 
CDK4/6 and MEK/ERK pathways with some of the predicted 
transcription factors (blue nodes) and their target genes (yellow nodes) 
from the 157 synergistically regulated genes. The green and red arrows 





The combined inhibition of CDK4/6 and MEK pathway has shown to be efficacious 





proliferation, colony formation and inducing apoptosis. Since this combination 
treatment strategy was proposed through the identification of the KRAS associated 
gene signature, we wanted to find out if the genes in the gene signature were 
downregulated. From the previous microarray performed, 27 out of the 37 genes in 
the signature were downregulated after the combination treatment (Figure 3.15A) 
with 12 genes synergistically downregulated (Figure 3.15B). This showed that by 
inhibiting CDK4/6 and MEK pathway, the upregulated KRAS dependency gene 
signature, likely crucial for the survival of KRAS-dependent cancer cells, can be 
abrogated. Another observation is that MEK inhibition alone was able to 
downregulate these genes to a certain extent and since single inhibition of MEK has 
proved to be ineffective in clinical settings, it is likely that the residual expression of 
these genes after MEK inhibition was sufficient to drive the survival of the cancer 
cells. Only after combination with CDK4/6 inhibition, the expression of these genes 
was then probably abrogated to a degree that is insufficient for the cancer cells to 
survive. Validation of the microarray data was performed using qPCR in KRAS 
dependent DLD1 and HCT116 showing a large decrease in representative KRAS 
dependency gene signature genes FOXM1, BUB1, PBK and CDCA7 under 
combination treatment (Figure 3.15C). Combination treatment in KRAS-independent 
HCT15, however, did not result in a further decrease in the expression of these genes 
as compared to single MEK inhibition (Figure 3.15D), mirroring the phenotypic lack 
of response seen in the earlier figures. These results suggest that the inhibition of both 
CDK4/6 and MEK pathway is able to downregulate the KRAS dependency gene 
signature and the change in the gene expression is consistent with the cell line 






Figure 3.15 KRAS Dependency Gene Signature is effectively downregulated 
by the inhibition of CDK4/6 and MEK in KRAS dependent CRC. 
A. Expression of KRAS dependent genes relative to 24h control in after 
treatment in DLD1 showed in a box and whiskers plot with the 25th and 
75th percentile indicated by the edges of the box with the median shown. 
Statistical significance was analyzed by paired Student’s T test. *P-value 
<0.05 and ****P-value <0.0001. 
B. 12 of the KRAS dependent gene signature synergistically downregulated 
by combination treatment in at least 1 of the time point. Expression fold 
change relative to 24h control in DLD1 from microarray data was plotted. 
C. qPCR validation of microarray data in KRAS dependent DLD1 and 
HCT116 on 4 representative genes, showing a robust downregulation by 
the combination treatment as compared to single treatment. 
D. RNA expression of 4 representative genes in KRAS independent HCT15, 
not showing much difference in expression in combination treatment as 
compared to single MEK treatment.  







3.6 Transcription factors crucial for cell cycle and mitosis, including FOXM1, 
are synergistically downregulated by CDK4/6 and MEK inhibition in KRAS-
dependent colorectal cancers 
Through the microarray data analysis comparing the combination treatment of 
CDK4/6 and MEK inhibitors to single treatment with either of the inhibitors, several 
transcription factors were identified to be possibly involved downstream of these two 
inhibited pathways, based on the genes that were differentially regulated in at least 
one of the treated groups as well as the synergistically downregulated genes in the 
combination treatment group. FOXM1, E2F1 and MYC were predicted through IPA 
and E2F4, FOXO3 together with FOXM1 and E2F1 were predicted through the 
computational simulation.  
FOXM1 has already been known to be a target of CDK4/6 and phosphorylated ERK, 
where these kinases phosphorylate FOXM1 at different sites, leading to its activation 
and nuclear localization where FOXM1 carries out its transcriptional activity (Ma, 
Tong et al. 2005, Anders, Ke et al. 2011).  As for E2F1, it is known to be indirect 
target of CDK4/6 where CDK4/6 phosphorylates RB and hyperphosphorylated RB 
releases E2F1 from its inhibitory binding pockets for E2F1 to allow it to activate 
transcription of its target genes (Choi and Anders 2014). C-MYC, an oncogene 
frequently amplified in cancer, is known to be phosphorylated and stabilized by p-
ERK (Sears, Nuckolls et al. 2000) amidst other regulation from pathways such as 








Figure 3.16 CDK4/6 and MEK inhibition synergistically downregulate 
FOXM1 and E2F1 in KRAS dependent CRC, but not in KRAS independent 
CRC  
A. Western blotting validation of inhibition of CDK4/6 and MEK pathway 
and also the complete downregulation of FOXM1, E2F1 and C-MYC on 
the protein level in combination-treated DLD1 and HCT116. (S.E. and 
L.E. indicate short exposure and long exposure respectively. 
B. Western blotting validation of inhibition of CDK4/6 and MEK pathway 
in KRAS independent HCT15 but without the complete downregulation 
of FOXM1 and E2F1 as seen in DLD1 and HCT116. 
C. Quantification of FOXM1 and E2F1 protein expression relative to each 





We validated the predicted involvement of these transcription factors by observing 
their protein expression after treatment with Palbociclib, PD0325901 or with both 
inhibitors. We treated KRAS dependent DLD1 and HCT116 for 48 hours, harvested 
the cells and lysed them for protein extraction. The effects of the inhibitors on 
CDK4/6 and RAS/MAPK pathway were first characterized (Figure 3.16A). Single 
Palbociclib treatment did not have much effect on the RAS-MAPK pathway as no 
significant changes were observed in phosphorylated ERK1/2 and C-MYC, unlike 
single MEK inhibition which was adequate to downregulate ERK1/2 phosphorylation 
and C-MYC expression. This suggests that C-MYC downregulation is not a critical 
determinant of the synergistic effect elicited by the combination treatment. 
Palbociclib or PD0325901 treatment alone led to only modest reduction in 
phosphorylated RB and E2F1, suggesting that CDK4/6 pathway was only partly 
inhibited. This may suggest the reason behind ineffective single MEK inhibition may 
be due to remnant CDK4/6 pathway activity and notably, by treating with both 
CDK4/6 and MEK inhibitors, phosphorylated RB and E2F1 expression were fully 
abrogated.  
Remarkably, FOMX1 and E2F1 which were predicted to be downregulated, showed 
synergistic downregulation in the combination treatment as compared to single 
treatment (Figure 3.16A, C) and FOXM1 downstream target, cyclin B1 also showed 
the same downregulation trend in both DLD1 and HCT116. For the other 
transcription factors predicted, E2F4 and phosphorylated FOXO3, their expression 
did not show any significant changes after combination treatment. 
Next, we repeated the same treatment for KRAS independent HCT15, which has been 
shown to be not responsive to the combined inhibition of CDK4/6 and MEK. If 
CDK4/6 pathway and FOXM1 downregulation is critical for the effective of the 
combination treatment, in the less responsive HCT15, the pathway and FOXM1 
should still be present after combination treatment. Indeed, the expression of 
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phosphorylated RB, FOXM1 and FOXM1 target cyclin B1 remained after 
combination treatment (Figure 3.16B, C). Single MEK inhibition in HCT15 led to 
only a very slight reduction in the expression of the components of the CDK4/6 
pathway (phosphorylated RB and cyclin B1) as compared to DLD1 and HCT116. 
This suggests that in the KRAS dependent CRC, the RAS-MAPK pathway may have 
a greater role in activating the CDK4/6 pathway whereas in the KRAS independent 
CRC, CDK4/6 pathway may be more strongly driven by another mitogenic pathway. 
This lent greater weight of the role of CDK4/6 pathway in KRAS dependent CRC 
and the rationale behind using CDK4/6 and MEK inhibitors in combination 
Since BRAF-mutant CRC also display activated MAPK pathway and are considered 
to be dependent on the MAPK pathway, we also treated two BRAF mutant CRC lines 
RKO and HT-29 with single or combined treatment of Palbociclib and PD0325901 
for 48 hours. A similar abrogation of FOXM1 and CDK4/6 downstream targets were 
also observed when compared to the KRAS dependent CRC lines (Figure 3.17). From 
all these data, it strongly suggests that the complete downregulation of CDK4/6 
pathway and its downstream signaling is crucial to inhibit proliferation in KRAS 



















Figure 3.17 Inhibition of CDK4/6 and MEK in BRAF mutant CRC 
downregulates FOXM1, Cyclin B1, E2F1 and C-MYC. 
Western blotting showing the complete downregulation of FOXM1 and its target 
gene, CyclinB1 and also the downregulation of E2F1 and C-MYC in BRAF 
mutant RKO and HT-29. 
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3.7 Combination treatment of CDK4/6 and MEK pathways leads to longer-
lasting repression of CDK4/6 pathway and FOXM1 expression as compared to 
single inhibitor treatment 
To explore the effect of Palbociclib and PD0325901 on CDK4/6 and MAPK 
pathways, we treated DLD1 and HCT116 with the two inhibitors individually and in 
combination and harvested the cells at 2, 4, 8, 24 and 48 hours for DLD1 and 4, 8, 24 
and 48 hours for HCT116. An observation that we first made was that single 
treatment of Palbociclib was able to downregulate the phosphorylation of RB, E2F1 
and FOXM1 over time up to 24 hours but at the 48 hour, there was a re-expression of 
phosphorylated RB, E2F1 and FOXM1 in DLD1 (Figure 3.18A). In HCT116, single 
treatment with CDK4/6 inhibitor was insufficient to completely downregulate 
phosphorylated RB and E2F1 at all time points (Figure 3.18B). For the MEK 
inhibitor treated cells, expression of phosphorylated RB and E2F1 was reduced but 
not completely abrogated in both DLD1 and HCT116. In the combination treated 
cells, however, phosphorylated RB, E2F1, FOXM1 and Cyclin B1, a target of 
FOXM1, remained downregulated after 48 hours. In HCT116, though FOXM1 
seemed to be completely abrogated with single CDK4/6 inhibition, it was only in the 
combination treatment that Cyclin B1 expression was completely eradicated. This 
suggests that the combined treatment of Palbociclib and PD0325901 is effective in 
repressing or even shutting down the CDK4/6 and MAPK pathways for a longer 
duration as compared to single inhibitor treatment and this can prevent the remnant 








Figure 3.18 Combined inhibitions of CDK4/6 and MEK repressed the 
activity of CDK4/6 pathway and FOXM1 for a longer duration in KRAS 
dependent CRC 
A. Western blotting showed longer suppression of the CDK4/6 pathway in 
the combination treated DLD1 as compared to single inhibitor treatment. 
B. Western blotting in HCT116 showed similar longer suppression of 





3.8 KRAS dependent and independent colorectal cell lines showed differential 
sensitivity towards FOXM1 depletion 
Earlier, we showed that upon inhibition of both CDK4/6 and MEK, FOXM1 and 
E2F1 were observed to be synergistically downregulated as compared to the single 
treatment in both KRAS-dependent DLD1 and HCT116 but in KRAS independent 
HCT15, and that the responsiveness of the cell lines to the combination treatment 
correlate with KRAS dependency. Thus we wanted to investigate if FOXM1 or E2F1 
were important to the cell viability. Short interfering RNA was used to knockdown 
FOXM1 and E2F1. For E2F1 knockdown, no effect was observed in cell viability 
(Figure 3.19A). This could be attributed the functional redundancy in the E2F family. 
Triple knockdown of E2F1, E2F2 and E2F3 were therefore carried out as they 
function as transcriptional activators but cell viability were still not affected (Figure 
3.19A). This could implies that the reduction of E2F1 seen in the combination treated 
cells was either an effect of the general reduction in growth or that there are other 
transcription factors that are able to replace the function of E2Fs when E2F1, E2F2 
and E2F3 are knocked down. E2F family regulates many genes that are involved in 
cell growth, mitosis and survival but often these genes are tightly regulated by many 
other transcription factors and so it is likely upon only E2F knockdown, the cell 
viability was not affected. However, the role of E2Fs in the combined inhibition of 
CDK4/6 and MEK should not be rule out because there are a few crucial transcription 
factors that are downregulated upon the combination treatment and so it is still 








For FOXM1 knockdown, reduction in cell proliferation (Figure 3.20B) and colony 
formation in soft agar (Figure 3.20C) were observed in both KRAS dependent DLD1 
and HCT116 but not in KRAS independent HCT15 (Figure 3.20A). It is also 
interesting to note that sensitivity to FOXM1 correlate with KRAS dependence 
(Figure 3.20C), suggesting that FOXM1 could be specifically important for the 
viability of KRAS dependent cancer cells. 
Figure 3.19 Knockdown of E2F1-3 did not affect cell viability  
A. Short interfering RNA sequences (30nM) were used to specifically 
knockdown E2F1, E2F2 and E2F3 in DLD1. Cell viability was measured 
with CellTiter-Glo. 
B. RT-qPCR validation of knockdown efficiency 
















Figure 3.20 KRAS dependent CRC displayed sensitivity to FOXM1 
knockdown  
A. Knockdown of KRAS in KRAS dependent DLD1 and HCT116 led to a 
more significant reduction in cell viability as compared to KRAS 
knockdown in KRAS independent HCT15. 
B. Knockdown of FOXM1 in KRAS dependent DLD1 and HCT116 led to a 
more significant reduction in cell viability as compared to FOXM1 
knockdown in KRAS independent HCT15. 
C. Knockdown of either KRAS or FOXM1 significantly reduced colony 
formation in anchorage independent conditions in KRAS dependent CRC 
DLD1 and HCT116 but not in KRAS independent HCT15. Unpaired 
Student’s T-test was used for statistical analysis. *P-value<0.05; **P-
value<0.01; ****P-value<0.0001. 
D. Validation of FOXM1 knockdown at RNA and protein expression level.  













We also performed FOXM1 knockdown in DLD1 KRAS isogenic cell lines, 
measured their proliferation and compared their growth to their respective negative 
control knockdown. We observed that the DLD1 parental and KRAS mutant lines 
displayed a significantly greater reduction in proliferation as compared to DLD1 
KRAS wild type line upon FOXM1 knockdown (Figure 3.21A). Here, we once again 
showed that CRC lines with KRAS mutation are more sensitive to FOXM1 
knockdown, suggesting FOXM1 is more important for the viability of KRAS mutant 
CRC than KRAS wild type CRC. 
  
Figure 3.21 KRAS mutant DLD1 displayed greater sensitivity to FOXM1 
knockdown as compared to KRAS wildtype DLD1  
A. Growth of DLD1 KRAS isogenic cell lines after knockdown of FOXM1 
with siFOXM1 (30nM) relative to siNC knockdown. Unpaired Student’s 
T test was used. ***P-values<0.001. 
B. qPCR validation of FOXM1 knockdown.  





3.9 FOXM1 depletion cooperates with MEK inhibition to reduce cell viability 
and KRAS dependency gene signature 
Since FOXM1 was downregulated in the Palbociclib and PD0325901 treated KRAS 
dependent cells and its expression important for the cell viability specifically in the 
KRAS dependent cells, we wanted to determine if knockdown of FOXM1 was able to 
cooperate with MEK inhibition. We first knocked down FOXM1 using short 
interfering RNA against FOXM1 and then after reseeding the cells, treated them with 
PD0325901. We found the combination of FOXM1 knockdown together with MEK 
inhibition led to a further decrease in proliferation and number of colonies formed in 
the anchorage independent soft agar specifically for KRAS dependent DLD1 and 
HCT116 (Figure 3.22 A, B). In KRAS independent HCT15, in 2D monolayer growth 
condition, the combination of FOXM1 knockdown and MEK inhibitor did lead to a 
significant reduction in growth when compared to FOXM1 knocked down cells 
(Figure 3.23A). However, in anchorage independent soft agar growth condition which 
is more representative of the in vivo tumor growth conditions, knockdown of FOXM1 
with MEK inhibition did not further reduce the number of colonies formed when 
compared to MEK inhibitor treatment only (Figure 3.23B). The concentration of 
PD0325901 used in these assay were the EC50 values of their respective cell lines, 
518nM for DLD1 and 126nM for HCT116. Lower concentrations of PD0325901 
were used for soft agar assays as cells were generally more sensitive when growing in 
this condition. However, for HCT15, a higher concentration of 1µM was used to 
ensure that the difference observed between KRAS dependent and independent lines 
was not due to the ineffective inhibition of MEK. Here, we showed that specifically 
in KRAS dependent CRC, MEK inhibition with FOXM1 depletion led to greater 
reduction in growth and cell viability. 
We also checked the representative genes from KRAS dependency gene signature 
upon the knockdown of FOXM1 and MEK inhibition and found that only in the 
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KRAS dependent cell lines, a cooperative decrease of these genes were observed 
(Figure 3.22C). In KRAS independent HCT15, even an increase of the RNA 
expression of CDCA7, BUB1 and PBK was seen when comparing the FOXM1 
knocked down and MEK inhibitor-treated sample to MEK inhibitor-treated only 
sample (Figure 3.23C). Even at the gene expression level, there was a distinct 
difference between KRAS dependent and independent CRC upon FOXM1 
knockdown and MEK inhibition and this corresponds to the susceptibility of these 
lines to the combination treatment. This further suggests the potential role that 













Figure 3.22 FOXM1 knockdown with MEK inhibition led to greater reduction 
in cell viability and expression of genes in the KRAS dependent gene signature 
in KRAS dependent CRC 
A. An increase reduction in cell viability in MEK inhibitor treated FOXM1 
knocked down cells in both KRAS dependent DLD1 and HCT116. EC50 of 
PD0325901 were determined for each of the cell lines and used for this 
assay. 
B. Significant reduction in the number of colony formed in anchorage 
independent soft agar after FOXM1 knockdown and MEK inhibition 
treatment. Concentration of PD0325901 used was reduced to better observe 
the combined effect of FOXM1 knockdown and MEK inhibition. Student’s 
T test was used. *, **,*** and ****P-values<0.05, 0.01,0.001 and 0.0001 
respectively. 
C. Total RNA were extracted after knockdown of FOXM1 for 72h and 
concurrent MEK inhibitor treatment in the last 24h. Representative genes 
from the KRAS dependency gene signature showed greatest 
downregulation after FOXM1 knockdown and MEK inhibition. 
Concentration of PD0325901 used was 512nM and 126nM for DLD1 and 
HCT116 respectively 


















Figure 3.23 No significant reduction in colony formation and expression of 
KRAS dependent gene signature upon FOXM1 knockdown with MEK 
inhibition in KRAS independent CRC  
A. An increase reduction in cell viability in MEK inhibitor treated FOXM1 
knocked down HCT15 (KRAS independent) in 2D monolayer growth 
condition. 1µM PD0325901 was used. Paired Student’s T-test was used. 
***P-value<0.001. 
B. No significant cooperative reduction in colony formation seen in 
FOXM1 knocked down and MEK inhibitor treated HCT15 in anchorage 
independent soft agar. Unpaired Student’s T-test was used. N.s., not 
significant 
C. Total RNA were extracted after knockdown of FOXM1 for 72h and 
concurrent MEK inhibitor treatment in the last 24h. Representative genes 
from the KRAS dependency gene signature showed no reduction in 
FOXM1 knocked down cells with MEK inhibition when compared to 
MEK inhibitor treated cells. 






3.10 Combined treatment of CDK4/6 and MEK inhibitors in patients derived 
colorectal cancer lines 
So far we have been testing the combination treatment of Palbociclib and PD0325901 
in cell line models and these lines have been propagated in culture for many decades 
and may not be the best model to represent patients’ colorectal cancer cells. To this 
purpose, we obtained fresh primary colon tumors from patients after surgery, 
mechanically and enzymatically broke down the tissue to obtain the cells from the 
bulk tumor. These cells were then grown in serum-free growth medium supporting 
the growth of tumor spheres when grown in a low attachment conditions. This was 
done in order to eliminate the other cell types such as fibroblasts which are also found 
in the bulk tumor. If grown on plastic and supplemented with growth medium 
containing serum, the culture will be a mixture of fibroblasts and cancer cells and 
since cancer cells have the capability to grow in an anchorage-independent and 
serum-free condition, they can be selected for by using this culturing method. This 
method also enriched for cancer stem cells thus we can use this system to observe the 
effect of combination treatment on cancer stem cells. 
We successfully established 3 patient derived sphere lines namely 14S, 29S and 47S 
and they can be passaged up to at least 25 times. We further characterized their 
KRAS mutation at G12 and G13 codon and BRAF mutation at V600 using 
pyrosequencing and found 14S harboring a heterozygous KRAS G13D mutation, 29S 
having a homozygous KRAS G12 and 47S having no KRAS mutation (Table 3.2). 
BRAF-V600 mutation was not detected in any of the lines. As with all sequencing 
techniques, there is a possibility of false positive detection so we have previously 
tested on a range of CRC cell lines with known mutation status to obtain a false 
positive rate of 5-10% for this method of mutation detection. For 14S, it is not 
immediately conclusive that it is a KRAS heterozygous mutant as mutation detection 
from 40-60% can either mean 50% of the population having a wildtype status and the 
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other 50% having a homozygous KRAS mutation. To be sure, we needed to derive a 
few separate lines from single cell and check their mutation status. However, sphere 
cells when grown in single cells or under low seeding density did not grow well to 
form spheres. To overcome this problem, we derived adherent lines from the patient 
derived spheres lines 14S and 47S, and named them 14SA and 47SA respectively. 
For 14SA, we further made subclones where we seeded the parental 14SA line in 
very low density, such that single cells were separated and clones arising from single 
cells were clearly separated. Clones were carefully trypsinized to avoid cross 
contamination between clones and removed and placed into a 24-well plate for 
expansion. Upon obtaining sufficient cells, pyrosequencing was carried out and we 
found all the clones, including the parental 14SA, harboring about 50% of KRAS 









Table 3.2 Summary of KRAS mutation status of patient tumor derived lines 
determined via pyrosequencing.  
Homozygous KRAS mutant and wild type were determined solely through 
pyrosequencing. Single clones from 14SA were expanded and sequenced together 




We went on to further characterize their RNA expression prolife where we examined 
the expression of the genes from the KRAS dependency gene signature such as 
FOXM1B, FOXM1C, CDCA7, BUB1 and PBK and also CDC20 and CCNB2 which 
are known FOXM1 target genes and found 47S to have the highest levels of FOXM1 
(Figure 3.24). It might seem contradictory to our prior finding that KRAS mutant 
cancer cells were likely to express higher levels of the KRAS dependency gene 
signature but upon closer inspection of the gene expression profile of all the three 
groups of tumors in Figure 3.1B, there were some KRAS wildtype tumors which 
possess similar elevated levels of the KRAS dependency gene signature. 47S also 
exhibited relatively higher level of phosphorylated ERK as compared to 14S and 29S 
(Figure 3.24), indicating that the RAS/MEK/ERK pathway was highly activated in 
the cells despite having wild type KRAS. Higher MAPK activity suggests greater 
dependence on this pathway. Thus, this suggests the KRAS dependency gene 
signature can better predict the activity of RAS/MEK/ERK pathway, and hence may 





Figure 3.24 Expression of genes from KRAS dependency gene signature in 
patient tumor-derived sphere lines.  
(Left) Expression of representative genes from KRAS dependency gene signature 
as well as FOXM1 target genes CDC20 and CCNB2. Normalization was done 
with 18S and expression from 29S and 47S was plotted relative to 14S. (Right) 
Protein expression of phosphorylated ERK in the patient tumor derived sphere 
lines. 




We then proceeded to test and treat 3 patient tumor-derived sphere lines with 
Palbociclib, PD0325901 and the combination of both and measured their cell viability 
at day 7 and 14 after drug treatment. Concentration of inhibitors used was optimized 
such that single inhibitor treatment only led to about 50% reduction in viability. The 
growth of all three lines was significantly more inhibited by the combination 
treatment as compared to the single treatment (Figure 3.25A). If the status of KRAS 
mutation was used to predict the response to the combination treatment, we would 
expect 47S to not respond to the treatment. However, we observed that 47S, together 
with 14S and 29S showed significant further reduction upon treatment with both 
CDK4/6 and MEK inhibitors as compared to single treatment. This observation in 
47S better correlated to its level of KRAS dependency gene signature, especially the 
level of FOXM1 in 47S than to its KRAS wild type status.  
We also further treated of 29S and 47S with the same drug concentration used in 14S. 
In figure 3.25A, the growth of the spheres were not completely abrogated but with 
higher concentration of MEK inhibitor used, the growth of the sphere lines could be 
further reduced (Figure 3.25B). Notably, the concentrations of the inhibitors used 
here are in nanomolar range, and so highlights the efficacy of inhibition of the 
CDK4/6 and MEK in treating patient CRC–derived spheres, especially those with 
high level of KRAS dependency gene signature expressed such as 47S. 
We did not have more lines to validate our findings but our preliminary findings 
supported our earlier stand that KRAS mutation might not be the best biomarker to 
predict the response to combination treatment. Instead, the KRAS dependency gene 
signature may be a more accurate method to determine the level of KRAS 
dependency of the tumor and thus be able to better predict the tumor response to the 
combination treatment. More lines need to be generated and tested in order to obtain a 
more conclusive and significant result on the KRAS dependency gene signature being 










Next, using the 14SA line, we treated the cells with Palbociclib and PD0325901 alone 
or in combination for 48 hours and harvested the cells for RNA to examine the 
expression of the respective genes of the KRAS dependency gene signature. We 
found that 14SA responds similarly to the KRAS dependent DLD1 and HCT116 
where the combination treatment was able to significantly reduce the expression of 
the respective genes to a greater degree as compared to single treatment (Figure 3.26).  
Figure 3.25 Combined inhibition of CDK4/6 and MEK significantly reduces 
viability in patient tumor-derived spheres.  
A. Cell viability of patient CRC tumor derived sphere lines 14S, 29S and 47S 
were measured after 7 and 14 days of treatment with top up of fresh media 
and drugs at day 7.   
B. Cell viability of patient CRC tumor derived sphere lines 29S and 47S 
were measured after 14 days of treatment with top up of fresh media and 
drugs at day 7 with similar concentration of drugs used for 14S. Statistical 
analysis was done with paired Student’s T test. *p<0.05, **p<0.01, 
***p<0.001. n.s.= not significant. 






Once again, using a model derived from patient tumor, we showed the combined 
inhibition of CDK4/6 and MAPK pathway was able to target and downregulate the 





Figure 3.26 Combination treatment of CDK4/6 and MEK inhibitors in 
patient derived CRC line downregulates expression of genes in the KRAS 
dependency gene signature 
14SA (adherent line derived from 14S) was treated for 48 hours with CDK4/6 and 
MEK inhibitors at the indicated concentrations and total RNA was extracted. RT-
qPCR was then carried out on selected genes from KRAS dependency gene 
signature. Statistical analysis was performed with paired Student’s T test. 




3.11 Therapeutic effect of combined CDK4/6 and MEK inhibitors treatment in 
vivo 
Up to this point, all the experiments involving the testing of the efficacy of the 
combined inhibition of CDK4/6 and MAPK pathways had been done in vitro. For the 
better understanding on how the tumor would respond to the combination treatment 
of Palbociclib and PD0325901, we used xenograft models of KRAS dependent DLD1 
and BRAF mutant RKO where the cells were injected into the flanks of mice. Upon 
tumor formation, the mice were treated with either vehicle, Palbociclib, PD0325901 
or a combination of both for 14 or 17 days for DLD1 and RKO respectively. 
Combination treatment led to a greater reduction in tumor growth in both xenografts 
as compared to single treatment (Figure 3.27A, B). In addition, the same 
downregulation in the protein expression of phosphorylated RB, E2F1, FOXM1 and 
FOXM1 target cyclin B1 were observed to a greater extent in the combination 
treatment (Figure 3.28A, B). Importantly, there was no overt toxicity seen in the 
combination treated mice, as there was no more than 10% loss in weight when 
compared to the initial weight of the mice at the start of the experiment (Figure 
3.27C). All in all, through the in vivo animal study, we showed the combined 
inhibition of CDK4/6 and MAPK pathway using Palbociclib and PD0325901 to be 
effective in vivo and yet does not cause overt toxicity to the mice. This, together with 
the in vitro data, supports the use of Palbociclib and PD0325901 in KRAS dependent 







Figure 3.27 CDK4/6 and MEK inhibitors in combination effectively reduce 
tumor growth in KRAS dependent and BRAF mutant CRC xenograft 
models. 
A. DLD1 xenograft tumor growth in NOD/SCID mice treated with 
vehicle (n=9), 35mg/kg Palbociclib (n=10), 20mg/kg PD0325901 
(n=5) or combination (n=6). Mean tumor volume ± s.e.m. was shown. 
*P<0.05. 
B. RKO xenograft tumor growth in NOD/SCID mice treated with vehicle 
(n=9), 50mg/kg Palbociclib (n=10), 20mg/kg PD0325901 (n=8) or 
combination (n=7). Mean tumor volume ± s.e.m. was shown. 
*P<0.05, ***p<0.001 
C. Body weight change (± s.e.m.) in mice with DLD1 and RKO 


















Figure 3.28 CDK4/6 and MEK inhibitors inhibit expression of FOXM1 
together with signaling members of CDK4/6 and MEK pathway in vivo. 
A. Western blot analysis of indicated proteins from resected DLD1 
xenograft tumors. 



















4.1 Role of CDK4/6-FOXM1 axis in KRAS driven colorectal cancer 
In our study, we have, through the derivation of the KRAS dependency gene 
signature from colorectal cancer tumors, hypothesized that the activity of CDK4/6 
pathway is important in KRAS dependent/KRAS driven cancer. The gene signature 
being enriched for cell cycle and mitotic processes  as well as the presence of 
FOXM1 and its target genes, PBK, MCM3, BUB1B, CDK2, TRIP13 and KIF11 
(Buchner, Park et al. 2015), has suggested the involvement of CDK4/6, as it is a 
major player in the G1/S checkpoint and it phosphorylates and activates FOXM1. 
Initial studies on RAS-transformed cells showed that the loss of function of tumor 
suppressor RB, which activity is regulated by CDK4/6,  is necessary for the 
prevention of RAS oncogene-induced senescence, suggesting that these two pathways 
cooperate to drive robust cell growth (Collins, Napoli et al. 2012). Although loss of 
RB is rarely observed in colorectal cancer, CDK4/6 pathway is frequently activated 
as seen by the occurrence of CCND1 amplification and aberrant methylation of the 
CDKN2A locus, resulting in the increase in CDK4/6 activation and 
hyperphosphorylation and inactivation of RB as mentioned in chapter 1.3.4. This 
suggests that in CRC, through the activation of CDK4/6 pathway instead of RB loss 
of function might be involved in the prevention of RAS oncogene-induced 
senescence. 
Downstream effectors of KRAS have also been known to regulate components of the 
CDK4/6 pathway. Together with the AKT pathway, phosphorylated ERK 
phosphorylates and activates AP-1 , promoting the binding of AP-1 proteins to the 
CCND1 promoter and increasing cyclin D1 transcription and expression(Shaulian and 
Karin 2001). eIF4E downstream of AKT too promotes cyclin D1 post-translationally 
via increasing nuclear export of CCND1 transcripts together with a sub-set of growth-
related mRNA (Rousseau, Kaspar et al. 1996, Culjkovic, Topisirovic et al. 2005). 
CDK4 has also been shown to regulate and activate FOXM1 together with 
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phosphorylated ERK, another indication that the KRAS/MEK/ERK and CDK4/6 
pathway cooperate to drive cell cycle and mitosis, since FOXM1 is vital for the 
transcription of various genes important for mitotic phase. 
Tumors with RAS mutation frequently displayed significantly higher levels of mitotic 
figures (Liu, Jakubowski et al. 2011) and in melanoma cell lines, a knockdown of 
NRAS led to reduction in many cell cycle genes (Kwong, Costello et al. 2012). Here, 
our study also reveals that cancer cells that are dependent on KRAS are dependent on 
FOXM1 as well and this is not surprising as FOXM1 is required for transcription of 
genes that are important in mitosis. Activation of KRAS increases cell proliferation 
and this suggests that KRAS may drive proliferation partly through FOXM1. All in 
all, prior research and our studies suggest that the CDK4/6 pathway and KRAS 
driven pathways interact at many levels and that for KRAS mutation to exert its 
oncogenic effect in the cells, it requires the dysregulation and subsequent activation 




4.2 Targeting CDK4/6 and MAPK pathway as a potential therapeutic strategy in 
KRAS dependent CRC 
Previous studies used Palbociclib as a single agent at higher dosage up to 150mg/kg 
(Fry, Harvey et al. 2004) in order to achieve a substantial reduction in tumor growth. 
In our studies, an addition of a suboptimal dosage of 30mg/kg of Palbociclib together 
with PD0325901 was sufficient to achieve a reduction in tumor growth, suggesting 
the inhibition of the CDK4/6 pathway synergizes with the inhibition of MEK/ERK 
pathway to elicit anti-tumor growth in KRAS dependent and BRAF mutant CRC. 
And this combination treatment was shown to be well-tolerated in the animal studies. 
This effective halting of KRAS-dependent tumor growth could be due to the 
abrogation of expression of important transcription factors FOXM1, E2F1 and 
CMYC. In the single MEK inhibitor-treated DLD1 and HCT116, only the expression 
of CMYC was almost completely downregulated with FOXM1 and E2F1 expression 
slightly reduced.  The inhibition of MEK prevents the activation of effectors 
downstream such as RSK, ELK-1 and ETS-2 which would decrease translation and 
transcription machinery. However, with the presence of E2F1 and FOXM1, which 
together regulates genes involved in all phases of cell cycle (Bracken, Ciro et al. 
2004, Costa 2005), the cancer cells may still have sufficient activating signaling to 
continue with cell cycle progression.  
Cell cycle progression is tightly regulated by cyclin-dependent kinases and their 
binding cyclins which upon activation or repression regulate a complex network of 
transcription factors and many of the transcription factors shared the same target 
genes, leading to redundancy. Through microarray gene expression analysis after 
combination, we identified three important transcription factors that are 
downregulated together with their target genes and analysis using IPA also revealed 
that cell cycle and mitosis pathways are significantly downregulated. All these 
suggested that it is likely that the inhibition of CDK4/6 and MEK could have 
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inhibited the activity of pro-survival and pro-proliferation transcription factors 
beyond a certain threshold to inhibit growth and even trigger apoptosis. 
Malumbres et al had shown that the loss of CDK4/6 did not affect mouse embryo 
development and that mouse embryonic fibroblasts lacking CDK4/6 were still able to 
proliferate (Malumbres, Sotillo et al. 2004). In parallel, Kozar et al knocked out D-
type cyclins in mice and found that in their absence, there are other alternative 
mechanisms to enable the cell cycle progression (Kozar, Ciemerych et al. 2004), once 
again demonstrating that CDK4/6 is not vital for normal cell survival and 
proliferation. The discovery of CDK1 as the likely predominant cyclin-dependent 
kinase in normal mammalian cells(Bashir and Pagano 2005), may explain why the 
use of CDK4/6 inhibitors is likely to be less toxic to normal cells.  
MEK inhibitor, though was shown largely to be ineffective in clinic other than 
BRAF-mutant and NRAS mutant melanoma when administered alone, is still 
considered to be potentially effective against KRAS or BRAF driven cancer due to its 
strategic location in the RAS/RAF/MEK/ERK pathway. The reasons limiting MEK 
inhibitor efficacy, specifically for PD0325901 for non-small cell lung cancer, in the 
clinical trials are toxicity and lack of primary objective response in patients (Haura, 
Ricart et al. 2010). However, with the discovery of compensatory pathways such as 
PI3K/AKT pathway being activated in the KRAS mutant cancer cells upon MEK 
inhibition, it is not surprising that even at high dose of MEK inhibitor which elicited 
toxicity, no objective response was observed.  
In our studies, we observed with single MEK inhibitor treatment, there was remnant 
of CDK4/6 activity as indicated by E2F1 and phosphorylated RB, which suggests that 
the insufficient inhibition of CDK4/6 by MEK inhibitor could be adequate from the 
survival of these cancer cells. Indeed, the combination treatment of both inhibitors 
completely shut down the CDK4/6 signaling and further potentiates the effects of 
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MEK inhibition on the cancer cells both in vitro and in vivo, suggesting that there is 
possibility of achieving objective response in clinical trials. 
Combination with MEK inhibitor with a dual PI3K and mTOR inhibitor, PF-
04691502, in phase 1 study failed to study the combined effects of both the inhibitors 
at their effective dose due to toxicity  (Zhao and Adjei 2014) and these may be a 
potential problem in our study. However, we have shown that there is no significant 
increase in apoptosis or growth retardation in the normal colon epithelial cells in the 
combination treated group as compared to the single inhibitor treated group. This 
should be due to the CDK4/6 being much downstream in the signaling cascade and its 
main function in regulating cell cycle entry. For PI3K or mTOR, they regulate a 
variety of cellular processes ranging from protein synthesis and translation to 
metabolism and proliferation. Thus, upon inhibition of PI3K or mTOR, these 
pathways which are also vital to normal cells will be affected whereas in CDK4/6 
inhibition, only cell cycle entry is inhibited. 
Moreover, there is an interesting observation that the normal epithelial cells in the 
presence of CDK4/6 inhibitor becomes more resistant to the effect of MEK inhibitor, 
suggesting that the combination treatment may increase the narrow therapeutic 
window of MEK inhibitor, resulting in less toxic effect as compared to single MEK 
inhibition treatment. This scenario where combination therapy results in fewer off-
targets adverse effects as compared to single agent therapy had been previously 
observed when BRAF and MEK inhibitors were used together (Flaherty, Infante et al. 
2012). Definitely, more in depth studies using in vivo models need to be carried out 
to verify if there is indeed a widening of therapeutic window, which if proven true, 




4.3 Conundrum of KRAS dependency and independency in KRAS mutant 
cancer and its therapeutic implications 
In our studies, we demonstrated the efficacy of the combination treatment of CDK4/6 
and MEK inhibitors in KRAS-dependent CRC cell lines. In KRAS independent CRC 
HCT15, the combination treatment was very much less effective and this could be 
due to the RAS/MEK/ERK pathway being less vital for survival and thus the 
combination treatment was not targeting the pathway that was crucial for viability. 
Our findings are in line with recent reports on the existence of KRAS mutant cancer 
cells whose viability are not impaired upon the knockdown of oncogenic KRAS 
(Scholl, Frohling et al. 2009, Singh, Greninger et al. 2009, Singh, Sweeney et al. 
2012). It is clear that we are underestimating the complexity of KRAS mutant 
cancers. Studies have shown that in pancreatic ductal adenocarcinoma, YAP 
amplification drives KRAS-independent tumor relapse in mice with TEAD and E2F1 
to promote cell cycle (Kapoor, Yao et al. 2014) and in mutant KRAS non-small cell 
lung cancer, expression of MUC1-C confers KRAS independence (Kharbanda, Rajabi 
et al. 2014). Thus it is time to develop more specific biomarkers that can predicts 
response to proposed therapeutic strategies in the future rather than to continue to use 
the status of KRAS mutation as the mode of stratification.  
Surprisingly, the KRAS wild type CRC cell line derived from patients tumor, 47S, 
which expressed relatively high amount of FOXM1 was also sensitive to CDK4/6 and 
MEK inhibition, suggesting that this combination treatment could be an effective 
treatment for KRAS wild type CRC as well. This also suggests that this cell line is 
dependent on KRAS and that the gene expression of the KRAS dependency gene 
signature is more accurate in predicting response to the combination treatment as 
compared to KRAS mutation status. This is not surprisingly as the activity of 
RAS/MEK/ ERK pathway is regulated by many components and it may be more 
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useful to examine the downstream output of the pathway to predict the response to 
the combination treatment. 
In light of the development of resistance towards anti- EGFR therapy in KRAS 
wildtype CRC where the emergence of KRAS mutant clone was detected in some 
patients, it may not be wise to continue to just treat KRAS wild type CRC with 
cetuximab and chemotherapy. Chemotherapy with cetuximab, monoclonal antibody 
against EGFR, could only increase the median progression-free survival from 8.7 to 
9.9 months (hazard ratio of 0.68) (Van Cutsem, Kohne et al. 2009) and studies are 
showing the presence of KRAS mutation clone in previously KRAS wild type 
classified tumor (Baldus, Schaefer et al. 2010, Richman, Chambers et al. 2011), 
suggesting that resistance is inevitable in these tumors. Morover, clinical trials have 
also shown KRAS mutant CRC to fare worse if cetuximab was given in addition to 
chemotherapy. Thus, it may be more beneficial to determine whether these KRAS 
wild type tumors are KRAS dependent and if so, the combination treatment be able to 





4.4 FOXM1 dependency in KRAS Dependent CRC 
In our findings, FOXM1 is observed to be important for the viability of KRAS 
dependent CRC as shown when FOXM1 was knocked down, proliferation and colony 
formation in anchorage independent condition was reduced. Likewise, the isogenic 
KRAS mutant CRC line is more dependent on the FOXM1 expression as compared to 
its KRAS wild type counterpart. Under MEK inhibition condition, addition knock 
down of FOXM1 further suppressed growth in monolayer and anchorage-independent 
conditions, as well as expression of representative genes from the KRAS dependency 
gene signature.  
This firstly showed that MEK inhibition is unable to completely deplete FOXM1 
expression and the remnant of FOXM1 expression may contribute to the survival of 
KRAS dependent CRC and the ineffectiveness of single MEK inhibitor treatment. 
Definitely, FOXM1 is not the only transcription factor vital for the survival of 
KRAS-dependent CRC as FOXM1 depletion is unable to completely recapitulate the 
phenotype elicited by the combined inhibition of CDK4/6 and MEK. However, it is 
intriguing as to how FOXM1 depletion only has an effect on KRAS dependent but 
not on KRAS independent CRC.  One major characteristic of KRAS driven cancer is 
that pathways associated with cell cycle and mitosis are highly enriched in these 
cancers which is not surprising since KRAS-transformed cells often displayed faster 
rate of proliferation (Tuveson, Shaw et al. 2004, Liu, Jakubowski et al. 2011). 
FOXM1 is known to transcriptionally activate genes essential to cell cycle, DNA 
replication, mitosis and DNA damage repair (Koo, Muir et al. 2012, Zona, Bella et al. 
2014). 
KRAS mutant cancer cells are often under replicative stress and are highly dependent 
on ATR/checkpoint kinase 1 (CHK1) for DNA damage repair (Gilad, Nabet et al. 
2010, Grabocka, Pylayeva-Gupta et al. 2014). Upon inhibition of CHK1, there is 
increased DNA damage and abrogation of G2/M checkpoint. Interestingly, FOXM1 
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is also reported to activate the transcription of CHK1 proteins together with MYC and 
E2F1 (Tan, Chen et al. 2010, Hoglund, Nilsson et al. 2011). In addition during DNA 
damage, checkpoint 2 (CHK2) also mediates stabilization of FOXM1 to activate 
expression of DNA repair genes (Tan, Raychaudhuri et al. 2007). Thus it could be 
possible that by depleting FOXM1 in KRAS-dependent CRC, DNA damage response 

















In our study, we have identified a gene signature that is associated with KRAS 
mutation from patient colorectal tumors and through pathway analysis carried out on 
the correlated genes that were upregulated in tumors with high KRAS mutation, 
pathways related to cell cycle and mitosis were observed to be enriched. Together 
with the observation that FOXM1 transcription factor was also upregulated in CRC 
tumors with high KRAS mutation, we hypothesized that the CDK4/6 pathway is also 
involved as a co-driver with the KRAS/MEK/ERK pathway in promoting the growth 
and proliferation of KRAS mutant CRC. 
Inhibition of CDK4/6 sensitizes KRAS dependent and BRAF mutant CRC to MEK 
inhibition, but not in KRAS independent CRC. Combination treatment with CDK4/6 
and MEK inhibitors reduces cell viability, induces apoptosis and downregulate the 
KRAS dependency gene signature in only KRAS dependent CRC. Importantly, 
treatment with Palbociclib and PD0325901 led to decreased tumor growth in vivo 
xenograft models with no overt toxicity,  
We have also demonstrated that the combination treatment downregulates mitotic 
transcription factor FOXM1 in a synergistic manner together other cell cycle 
transcription factors such as E2F1 and CMYC and this may potentially contribute to 
the synergistic action of CDK4/6 and MEK inhibition. In addition, our study showed 
that KRAS dependent CRC is also dependent on FOXM1, suggesting FOXM1 plays 
a important role in the viability of KRAS dependent cancers. 
In conclusion, our study identified a KRAS dependent gene signature and established 
a promising therapeutic strategy against KRAS dependent CRC via the inhibition of 





In our study, we are the first to use the combination of pyrosequencing technology 
and gene expression analysis to identify a KRAS dependency gene signature in 
patients CRC tumor samples. Through the use of quantitative KRAS mutation 
detection, we overcame the issue of intratumoral heterogeneity that previously 
hindered the identification of a KRAS associated expression prolife from tumor 
samples. 
We have also proposed and validated a treatment strategy for KRAS dependent and 
BRAF mutant CRC using a combination of CDK4/6 and MEK inhibitors, 
demonstrating in vivo efficacy with a satisfactory safety profile in the animal model 
used. Moreover, Palbociclib and PD0325901 have been well-studied in clinical trials, 
with the former already approved for use in clinic, thus allowing easier translation of 
this treatment strategy into future clinical trials. This will be of great significance as 
currently there is no targeted therapy available for KRAS mutant CRC. 
We have also shown normal colon epithelial cells to be less sensitive to the effects of 
the combination treatment as compared to single MEK inhibition. MEK inhibitors 
previously failed in clinical trials due to toxicity and lack of efficacy when given as a 
single treatment. This could imply that combination treatment may have a wider 
therapeutic window than MEK inhibitor alone. At best, additional CDK4/6 inhibition 
may even reduce adverse toxicity induced by PD0325901 and yet more effectively 
target the cancer cells. 
We have also shown FOXM1 to be important in CRC lines that are dependent on 
KRAS. FOXM1 together with the rest of the KRAS dependency gene signature can 
be further developed as a biomarker for the positive response to this proposed 
treatment strategy. Upregulation of the RAS/MEK/ERK pathway is not solely 
determined by KRAS or BRAF mutation status but is also determined by changes in 
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other activators, repressors and negative feedback mechanism. Therefore, by utilizing 
this gene signature, we can more effectively identify not only tumors with KRAS 
mutation but also tumors with elevated RAS/MEK/ERK signaling which we predict 
to be responsive to the combination treatment of CDK4/6 and MEK inhibitors. Since 
the gene signature is the summation of transcriptional output from different upstream 
signaling and signaling generated by a myriad of genetic and epigenetic changes, it 
will definitely be more informative than just KRAS mutation status, considering the 





5.3 Future Prospects 
We have identified a KRAS dependency gene signature specifically from CRC 
tumors samples that will be useful in the prediction of KRAS dependency and 
responsive to CDK4/6 and MEK inhibitor treatment. However, more validation needs 
to be done on a larger cohort of patient tumors to obtain their level of expression of 
the gene signature and simultaneously, culture the tumor cells in vitro to test their 
response to CDK4/6 and MEK inhibitors treatment. This will be the best way to 
prove the reliability and the clinical utility of the KRAS-dependency gene signature. 
Further work can also be done to refine the gene signature by selecting genes which 
exhibit better association with response to CDK4/6 and MEK inhibition.  
Based on our data, we have shown KRAS dependent CRC to be dependent on 
FOXM1 as well and this could be due to KRAS driven cancers having high levels of 
replicative stress, resulting in a dependency on DNA damage response pathway in 
which FOXM1 has also a critical role. Reports have shown the FOXM1 regulates 
expression of CHK1 and FOXM1 is a downstream effector of CHK2, a hint that 
KRAS dependent CRC may be dependent on FOXM1 due to its role in DNA damage 
response.  Furthermore since MYC and E2F1 are also reported to regulate expression 
of CHK1, it will be interesting to investigate if the combined inhibition of CDK4/6 
and MEK abrogate the activity of CHK1 and CHK2 since the combination treatment 
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